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ABSTRACT
Laboratory studies have demonstrated that some radioresistant tumours are 
hypersensitive to low doses of radiotherapy (<1Gy) and characteristically 
display features of radioresistance at more conventional radiation doses (2Gy 
per fraction), i.e. there is excess cell kill at doses <1Gy relative to that 
predicted by the linear quadratic (LQ) model. This phenomenon is called “low 
dose hyper-radiosensitivity” (LDHRS).
The aim of this thesis was to investigate if LDHRS could be demonstrated in 
tumours and in normal tissues and to assess whether there was a difference 
between them that could be exploited clinically. The epidermal basal cell 
layer of human skin was chosen as a model of normal tissue.
8 patients with metastatic tumour nodules to skin were recruited. The 
nodules were measured, their volume calculated and randomised to receive 
conventionally fractionated radiotherapy (1.5Gy/day) or ultrafractionated 
radiotherapy (0.5Gy TDS with a 4hr inter-fraction gap). Both groups were 
treated for 12 days. Measurements were taken on days 0, 5,8,12 & 26 and 
monthly until regrowth occurred. Time to regrowth to original volume was 
calculated and compared between groups using the Wilcoxon Signed Rank 
test. In addition skin biopsies were performed on days 0, 5, 8, 12 and 26; 
changes in BCD were compared using non-linear regression analysis. 
Proliferation was assessed using the proliferation markers Ki67 and Cyclin A.
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Analysis of all re-growth data demonstrates greater tumour growth delay in 
the nodules treated with the “ultrafractionated” regime. This was most 
marked in tumours generally accepted as being radioresistant and known to 
show LDHRS in vitro, 2-tailed p-value 0.009. Analysis of the surrounding 
normal skin does not demonstrate any evidence of LDHRS The proliferative 
response was similar in both treatment groups.
In-vitro experiments carried out in parallel failed to demonstrate LDHRS 
following multiple low doses of radiation in Hs633T - a sarcoma cell line that 
has demonstrated LDHRS to single low doses.
It was concluded that there was a potential therapeutic window that could be 
exploited by using "ultrafractionated" radiotherapy for the treatment of 
“radioresistant" tumours ". A feasibility study of "ultrafractionated" radiation in 
high-grade glioma (HGG) was initiated, with the ultimate aim of a larger 
phase II study. To date 2 patients have been recruited to the feasibility study.
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OBJECTIVES OF THESIS
The aim of this thesis was to investigate whether or not LDHRS could be 
demonstrated in tumours and in normal tissues and to assess if there was a 
difference between them that could be exploited clinically in the treatment of 
tumours classically described as "radioresistant". This requires:
A model of normal tissue radiosensitivity. Human skin has been 
selected as it lies in the primary radiotherapy field more frequently than any 
other normal tissue. It is readily observable and the early and late reactions, 
at doses above 1 Gy/fraction following radiotherapy have been well 
documented. The choice of skin as the organ of interest for the assessment 
of normal tissue response allows correlation with historical data and forms 
the basis of analysis of other normal tissues for LDHRS.
Accessible tumours. Metastatic tumour nodules to skin were chosen; this 
enabled us to compare the effects of multiple low doses on the nodules and 
on the surrounding normal skin. It also allowed ease of dosimetry and 
tumour nodule measurement.
A suitable "radioresistant" primary tumour to assess the feasibility of 
using an "ultrafractionated" radiotherapy regime. High-grade glioma 
was chosen because as well as being an aggressive tumour with an 
appalling clinical outcome, LDHRS has been demonstrated in glioma cell 
lines and xenograft models.
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CHAPTER 1: INTRODUCTION
1.1 Radiobiology applied to radiotherapy
1.1.1 Developments in radiotherapy
The use of ionising radiation for the treatment of malignant disease has 
undergone many changes over the course of the last century. The 
development, in the 1970’s, of Computerised Tomography Scanning (CT), 
and in the 1980’s of Magnetic Resonance Imaging (MRI) have 
revolutionised tumour diagnostics and the anatomic work-up for radiation 
planning. This phase matured in the 1990’s and has been amplified by an 
equally important development of radiotherapy equipment.
The past 30 years, therefore, have seen dramatic advances in the standard 
practice of radiation oncology; these have been mainly related to improved 
definition of the treatment volume with novel imaging techniques and the 
development of higher energy photon and electron sources with which these 
tumour volumes can be treated. As well as all this, major developments in 
radiotherapy fractionation have taken place developed largely from 
experimental and theoretical studies in radiation biology. In parallel with 
these advances, local control and 5-year survival rates have improved in a 
large number of tumours.
It does not seem unreasonable to expect a similar improvement in treatment 
outcome over the next number of years stemming from improved 
understanding of the mechanisms of action of both radiation damage and
17
treatment resistance and the application of therapies that target the specific 
characteristics of each tumour phenotype.
The biological effect of radiation on both tumours and normal tissues is 
dependent on a number of factors, namely total dose, dose per fraction, time 
between fractions and overall treatment time - the fractionation schedule 
used is as important as the dose delivered to the target tissues.
The introduction in the 1980’s of the Linear-Quadratic (LQ) model allowed 
the most accurate estimation of dose-fractionation response over the dose 
range from large single doses down to doses per fraction of about 2Gy. The 
model describes the shape of the cell survival curve and the response of 
both tumour and normal tissues to changes in fraction size in terms of the 
same 2 parameters a and p and their ratio a/p~The clinical significance of 
this was recognised by Thames et al [1]. They realised that the differences 
in a/p ratios for early and late responding tissues could explain the 
differences in response of these organs to changes in fraction size and thus 
provided much of the impetus for the clinical interest in altered fractionation 
schedules.
At doses of more than 1Gy, early reacting tissues or tumours demonstrate 
predominantly a linear relationship (a component) between dose and effect. 
Late reacting tissues demonstrate a large part of their effect to the square of 
the dose prescribed (p component). This is described by the equation:
18
S = exp ( - a d -  pd2)
Where S is the probability of survival, a is thought to be related to linear cell 
kill due to single track events, and p is thought to be related to quadratic cell 
kill due to two track events. See Figure 1.1
txD
SF
High LET
12 160 4 8
Radiation dose (Gy)
Figure 1.1. Graphical representation of linear quadratic model. See text for 
explanation. (Steel 3rd Edition)
This is a continuously bending curve. It’s shape is determined by the ratio 
a/p which is the dose at which the linear contribution to damage (aD) equals 
the quadratic contribution (PD2), a higher ratio of a/p indicates a more linear 
survival curve and correspondingly less effect of fractionation. An a/p ratio
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of 3 is common for late responding normal tissues; this means that at 3Gy 
the linear cell kill is equal to the quadratic repairable cell kill of D2 term. 
Tumours and acutely responding normal tissues have an a/p ratio of about 
10 and therefore larger doses per fraction are better tolerated. The response 
of cells to densely ionising radiation e.g. neutrons is almost an exponential 
curve.
The biological basis of the LQ model is still debated, but it is widely used to 
model and predict the increase in total dose with decreasing dose per 
fraction needed for an iso-effective response to radiotherapy in normal 
tissues and tumours [1,2]. The model reflects the gradual decrease in 
radiation effectiveness with lowered doses due to these doses being further 
back on the shoulder of the underlying survival curve for the cells at risk. It 
has been successfully applied to a broad range of in-vivo and in-vitro 
experiments and is the currently accepted method of calculating isoeffect in 
radiotherapy [2].
1.1.2 Low Dose Hyper-radiosensitivity
Until recently laboratory confirmation of cell survival at doses less than 1Gy 
was limited due to the difficulty in defining cell populations and surviving 
colonies at such low doses. For many years the low dose region of the cell 
survival curve was predicted to follow the extrapolation of the LQ model, as 
accurate measurement in this region was not possible by conventional 
methods. These conventional “Puck and Marcus” [3] survival assays relied
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on a certain number of cells being plated as a result of multiple dilutions. 
There are considerable errors inherent when using this method, including 
sampling errors, and the precise number of cells being plated may not be 
known.
Now however the availability of the Fluorescent-Activator-Cell-Sorter (FACS) 
and the Dynamic Imaging Processing Scanner (DMIPS) has enabled cell 
survival at low doses to be determined by defining cell number in irradiated 
populations more accurately [4].
The DMIPS is an automated microscope that scans a flask containing single 
cells, identifies the attached cells and stores their locations so that the exact 
cell positions can be revisited to manually score for colony formation. This 
allows a very accurate measurement of clonogenic survival on a cell by cell 
basis. The cell sorter uses the reflectance properties of cells when 
illuminated by laser light to sort individual cells on the basis of size and 
granularity without the use of a cell stain [5]. A precise number of cells can 
be plated before and after radiation, thereby omitting sampling error. These 
two methods have been used to measure the survival of tumour cells after 
very low doses of radiation.
Over the last decade work performed, mainly at the Gray Cancer Institute, 
has suggested that the LQ model does not apply at doses less than 1Gy 
and has identified a region of high sensitivity in the radiation survival 
response of mammalian cells at doses ~ 0.5Gy. This phenomenon is 
referred to as low dose hyper-radiosensitivity (LDHRS) and it precedes the
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occurrence of an area of relative resistance to cell killing by radiation (~0.5- 
1Gy) -  increased radioresistance (IRR). Above 1Gy the survival curve 
follows a smooth downward bending course in keeping with that predicted 
by the LQ model. LDHRS has been recorded in cell survival studies with 
yeast, bacteria, protozoa, algae, higher plant cells and insect cells [6] and 
there are now data available on over 50 human tumour cell lines of which 
>80% exhibit LDHRS [6-11]. Figure 1.2 shows a single dose cell survival 
curve using cell sort assay in T98G human glioma cells where the 
LDHRS/IRR at low doses is clearly evident [11].
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Figure 1.2: Survival of asynchronous T98G glioma cells irradiated with 
240kVp X-rays. The solid line represents the IR model and the dashed line 
represents the LQ model. At doses <1Gy the LQ model underestimates 
the effects of radiation. (Short 1999). The inset box is a close-up of the 
"low-dose" region of interest.
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Other mammalian cell lines that have been tested for LDHRS/IRR to date 
include colorectal cancer, melanoma, prostate cancer, bladder cancer, lung 
adenocarcinoma, sarcoma, cervical squamous cell cancer, neuroblastoma, 
one non-malignant epithelial line and one primary fibroblast line. As a 
generalisation it may be stated that it is those cell lines that are most 
resistant to 2Gy doses that exhibit the most marked LDHRS/IRR and a 
number of the cell lines that do not exhibit a hypersensitive response are 
very radiosensitive at 2Gy [6].
A new radiobiological model termed the "induced repair model of cell 
survival" was developed to better describe the LDHRS/IRR effect [12,13].
1.1.3 The Induced Repair Model
Joiner has proposed a new radiobiological model, termed the "induced 
repair model of cell survival" [12,13]. It is a simple modification of the linear 
quadratic (LQ) equation allowing modelling of the dose response 
relationship below 1Gy. In this model, the alpha parameter (a) describing 
radiosensitivity is allowed to vary with dose, becoming larger at low doses; 
the degree of radioresistance is therefore dose dependent. The LQ model 
describes the dependence of cell survival (S) on dose (d) according to the 
equation:
S = exp (-  ad -  pd2)
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In the Inducible Repair (IR) model, the basic LQ equation is extended (-ad is 
replaced) and becomes:
In this model, Or and Os describe sensitivity at high (conventional) doses and 
at very low doses respectively. Os is greater than Or, representing increased 
sensitivity at very low doses. Thus at low doses, the IR equation becomes 
the LQ equation with a = as and at high doses the IR equation is an LQ 
equation with a = Or. The parameter dc describes how rapidly this transition 
takes place with changing dose, so that when d = dc the change from a to otr 
is 63% complete. The (3 term from the LQ equation remains unmodified as 
this parameter only influences response at high doses.
Statistical fitting of this equation to the data from cell lines showing HRS has 
shown that this model is a good description of the observed outcome of low 
dose irradiation. Between different cell lines, Os is similar whilst (Xr varies 
considerably. Therefore since (Xr largely determines response to 
conventionally sized doses, the parameter a ja r indicates how much more 
sensitive cells would be at low doses compared with high doses, a ja r  has 
been found to correlate positively with the surviving fraction at 2Gy (SF2) 
and can reach values of 20 or more in those cell lines showing greatest 
high-dose resistance.
An alternative interpretation of this model would suggest that without “repair” 
mechanisms, all cells would follow the ots survival curve (as seen with 
neutrons). But the interaction of photons with DNA at the molecular level is 
fundamentally different and allows for some recovery of cell damage, 
accounting for the otr slope.
1.2 Possible mechanisms of low dose hyper-radiosensitivity (LDHRS)
Although now a well-established phenomena, the biological mechanisms 
underlying LDHRS/IRR are not fully understood. A number of hypotheses 
have been proposed but the precise explanation remains unclear. There 
follows a review of mechanisms that have been put forward.
26
1.2.1 Adaptive Response
It has been suggested that the phenomenon of LDHRS/IRR may be related 
to the “adaptive response” seen in some cell lines, where small initial doses 
of radiation induce resistance to a second higher dose [14-17]. This effect 
requires a time interval of several hours between the first and second 
radiation doses to occur, and like IRR, it is felt to be due to induction of 
repair mechanisms. If the adaptive response and LDHRS/IRR were 
consequences of the same underlying mechanisms then after a small initial 
conditioning dose there should be no LDHRS in response to a second dose. 
Marples et al [18] examined this using V79 hamster cells. They found that 
small priming doses of radiation induced resistance to a second given a few 
hours later. This effect was dependent on the initial dose given, with small 
initial doses (~20cGy) being more effective in abolishing second dose 
LDHRS than higher initial doses. They also noted that the induction of IRR 
in these cells was inhibited by cyclohexamide, which also inhibits the 
adaptive response in the same cell line. In these experiments 4-6hrs were 
needed for full induction of resistance with a return to the hypersensitive 
state occurring later again.
Although there appears to be a certain degree of homology between the 
adaptive response and LDHRS/IRR, a study by Wouters & Skarsgard [19] 
using HT29 cells suggests that they may be distinct phenomena. They found 
that priming doses prevent LDHRS but have no effect on the high dose
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region of the cell survival curve. Further by Short [20] has suggested that in 
a number of human cell lines the time course for the effect to become 
apparent and the persistence of the effect is much greater in the adaptive 
response, mitigating against a mechanistic relationship.
1.2.2 Apoptosis
Apoptosis is programmed cell death and is a distinct entity from necrosis. 
Apoptosis is defined by morphological changes resulting in non-pathogenic 
cell loss. Evidence suggests that apoptosis is not involved in any way in 
LDHRS/IRR. An original hypothesis had suggested that small doses of 
radiation lead to cells undergoing apoptosis, as a means of removing 
genomically unstable cells from the whole population. This was investigated 
in the LDHRS positive T98G cell line. This particular cell line exhibits 
LDHRS at doses of 0.4Gy, but there was no evidence of an increase in 
apoptosis at this dose [11].
In the glioma cell lines tested for the presence LDHRS/IRR, almost 90% 
exhibit it, but apoptosis is not the primary mode of cell death in glioma cell 
lines [21]. In both U373MG (LDHRS negative) and T98G (LDHRS positive) 
cell lines, apoptosis does not occur due to an abnormally high activity of 
protein kinase C (PKC), which promotes the production of a protein that 
leads to inhibition of apoptosis -  BCL-XL. However the inhibition of PKC 
induces apoptosis in these cell lines [22]. Power [23] investigated 2 cell
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lines, HT29 and Be11, characterised by high levels of LDHRS/IRR. She 
found that they exhibit differing levels of apoptosis in both irradiated and 
unirradiated populations over a wide range of doses. It is therefore generally 
accepted that there is no correlation between apoptosis and LDHRS/IRR.
1.2.3 Cell Cycle Effect
The possibility has also been raised that the LDHRS/IRR phenomenon may 
be due to various sub-populations of cells demonstrating differing levels of 
radiosensitivity, for example cells at different stages of the cell cycle -  the 
“two population” model. The argument being that at very low doses of 
radiation, cells in a particularly sensitive phase of the cell cycle would be 
eliminated and that this would influence the observed survival curve. 
Skarsgard [24] studied the low dose response of asynchronous and partially 
synchronised V79 cells and found such cell cycle effects did produce 
substructure in the asynchronous cells, but only at doses >1Gy.
Also, Short et al [11] examined T98G human glioblastoma cell lines and 
found that increased cell kill per gray is found at doses <0.5Gy in both 
asynchronously growing and G1 arrested cells. They concluded that 
LDHRS/IRR was a feature of the whole cell cycle and not due to a sensitive 
subgroup of cells. Mathematical modelling of the V79 data supported this 
supposition as 5% of cells would need to be -50-60 times more sensitive 
than the remainder of the population in order to lead to the changes in seen 
in radiosensitivity over the dose range 0-1 Gy [13].
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Further work by Short et al [25] has demonstrated a variation in the 
magnitude of LDHRS throughout the cell cycle. Looking at T98G cell line, 
survival curves demonstrate the greatest LDHRS/IRR during the G2/M 
phase. The LDHRS/IRR effect is present during G1 to a lesser extent and is 
virtually absent during S phase. This increase in LDHRS/IRR parallels 
changes in high dose radiosensitivity during different phases of the cell 
cycle. Variations in DNA repair capacity during different phases of the cell 
cycle seem, therefore, to have an effect on clonogenic survival after high 
and low doses per fraction. These experiments suggest that LDHRS is not 
due to a subpopulation of sensitive cells, as all cells selected on the basis of 
a single cell-cycle phase for an experiment showed a similar non-linear 
radiosensitivity.
Papathanasiou et al [26] have demonstrated that radiation induces 
expression of genes involved in cell cycle arrest, but this was a higher doses 
than those at which IRR occurs. However, there are data to suggest that 
radiation, in the dose range corresponding to IRR, does cause induction of 
cyclins that are involved in cell cycle control [27].
Despite these data Marples et al in their 1997 paper postulated that it was 
unlikely that IRR was due solely to cell cycle effects [28]. The fact that 
LDHRS/IRR occurs in synchronised cell populations suggests that it is not 
due to a cell-phase specific checkpoint defect [8,28].
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There is now evidence to suggest that although the HRS phenomenon 
occurs throughout all phases of the cycle, the magnitude of the effect varies 
with cell cycle phase [25]. It appears that LDHRS is primarily a G2 phase 
phenomenon and that the G2 response dominates that seen when 
asynchronous populations of cells are studied, although there is still an 
effect in G1.
This concept is given further weight by more recent work by Marples et al 
[29] who report that LDHRS may be explained by a substantial non-linear 
radiation dose survival relationship that is unique to cells in G2 and 
postulate that a recently identified G2/M checkpoint [30] may be implicated. 
This novel G2/M checkpoint occurs between 0 and 2 hours following 
radiation exposure, is dependent on ATM and is dose dependent over the 
dose range 0-1 OGy. Most importantly it has been shown to be inactive at 
doses less than ~0.4Gy. The apparent function of this checkpoint is to arrest 
the progression of G2 phase damaged cells, thus preventing entry in 
mitosis. What this translates into is that G2 cells irradiated with doses less 
than ~0.4Gy would enter mitosis early, while harbouring unrepaired DNA 
damage, and would die: thus giving the appearance of heightened 
radiosensitivity. It may be that a radiation-induced arrest of cells that are in 
G2 at the time of irradiation represents the means by which PARP-mediated 
recognition of DNA damage is linked to repair of those lesions necessary for 
the development of IRR. Therefore LDHRS is simply a manifestation of the 
absence of this process [29]. This remains to be verified at a molecular 
level.
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1.2.4 Alterations in DNA repair
Evidence has been accumulating that DNA repair is one of the main 
mechanisms underlying the LDHRS/IRR phenomenon. It was proposed that 
IRR results from activation of protective processes triggered by increasing 
levels of damage to the cell, while LDHRS is due to insufficient damage, that 
is not enough to trigger the mechanism [7,18,28]. Information gained from a 
number of studies using DNA repair modifiers and inhibitors of protein 
synthesis [18] point towards a need for the synthesis of new proteins 
involved in DNA repair for the development of IRR. This supports the theory 
that IRR reflects the induction of a radioprotective process. An alternative 
explanation may be that lower doses of radiation cause greater cell killing 
per unit dose because they cause little or no cell cycle arrest, during which 
time DNA repair would ordinarily take place. As stated previously [26] 
radiation, at higher doses than those at which IRR occurs can induce 
expression of genes involved in cell cycle arrest and there are data to 
suggest that radiation, in the dose range corresponding to IRR, does cause 
induction of cyclins that are involved in cell cycle control [27].
However, the fact that LDHRS/IRR occurs in synchronised cell populations 
suggests that it is not due to a cell-phase specific checkpoint defect [8,28]. 
Marples and Joiner [31] have studied the effects of radiation in the dose 
range 0-1 Gy on clonogenic survival of V79-379A cells in the presence or
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absence of three known modifiers of DNA repair, namely 3-aminobenzamide 
(3-AB), 9-D-arabino-furanosyladenine (ara-A) and novobiocin. The results 
gave a direct indication that specific DNA repair processes were probably 
involved in the mechanism of IRR. 3-AB inhibits the induction of IRR, so 
that the radiation response continues to follow the low dose hypersensitive 
pattern out to higher doses. This suggests that repair processes inhibited by 
3-AB may be directly or indirectly involved. 3-aminobenzimide blocks the 
repair pathways associated with poly (ADP-ribose) polymerase (PARP). 
PARP has been implicated in DNA damage detection following radiation- 
induced damage [32], possibly by inhibiting DNA ligase activity [33]. The 
inhibition of IRR by 3-AB suggests that the formation of single (ssb) or 
double (dsb) are important for the development of radioresistance. As 
regards the other agents, neither ara-A, which inhibits double strand repair 
by inhibition of DNA polymerase [34], nor novobiocin, which inhibits 
topoisomerase II and therefore prevents relaxation of supercoiled DNA 
before excision repair [35], prevented the development of IRR. They 
concluded that the DNA repair pathways most likely involved in IRR were 
probably inhibited by 3-AB.
This concept of a causal relationship between LDHRS/IRR and DNA repair 
processes was given further credence in a paper by Vaganay-Juery et al 
[36], which implied that decreased DNA-PK repair complex activity was 
involved in the HRS/IRR phenomenon. This was, however, contradicted in a 
later paper by Marples et al examining DNA-PK activity directly [37].
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1.3. The impact of Linear Energy Transfer (LET) and Hypoxia at low 
doses
The Linear Energy Transfer (LET) is defined as the mean energy given up to 
the medium by a particle travelling a distance of 1 pm. Differences in 
relative biological effectiveness (RBE) are dependent on the spacing of 
ionisation events in biological structures and high LET radiations, which are 
more densely ionising have a higher RBE. The presence of oxygen in the 
medium has an important influence on the outcome of radiation interaction. 
In the presence of oxygen hydroxyls, hydroperoxides and peroxides are 
formed, which are more stable than the initial radical species and can be 
very damaging to DNA. Oxygen therefore produces 'fixation' of radiation 
damage. This results in increased radiosensitivity in the presence of 
oxygen, which is quantified as an oxygen enhancement ratio (OER) defined 
as the ratio of doses which produce equal levels of cell kill in anoxic and 
aerobic cells respectively.
LDHRS has predominantly been demonstrated in low dose radiation 
experiments that have used low LET radiation. High LET produces a 
monoexponential survival curve with no substructure [13]. This suggests 
cell kill in the low dose range is LET independent with induced 
radioresistance occurring at higher doses with low LET radiation only.
The theoretical effects of hypoxia appear complex at low doses of ionising 
radiation. In published experiments, low single doses of radiation tend to 
reduce the OER [38,39]. Marples has confirmed the presence of LDHRS
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under hypoxic conditions [40]. The cell population studied was more 
resistant at high doses as expected but the resistant response was triggered 
at higher doses than in the oxygenated cells.
Denekamp and Dasu have attempted to model the interaction of cell 
survival, low dose radiation and hypoxia [41,42]. In contrast to the classical 
description of radioprotection in a hypoxic area their model suggests 
radiosensitization at low doses when LDHRS occurs in hypoxia. To achieve 
this effect it is assumed that in hypoxic cells the same level of free radical 
damage with induction of radioresistance occurs at a higher dose than in 
oxic cells. In the presence of LDHRS, the anoxic cells become more 
sensitive than oxic cells at around 1Gy. Laboratory experiments to 
substantiate this model are ongoing.
1.4. Evidence for the existence of LDHRS/IRR:
Evidence for the existence of LDHRS has been confirmed, excluded or 
disputed in cell line experiments, animal models and human normal tissue 
studies. Several laboratories using different techniques have confirmed the 
presence of LDHRS in a large number of cell lines.
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1.41. Cell survival assays
(A) Single low dose radiation exposure
There are now data available on the response of over 50 different human 
cell lines to single low dose radiation exposures of which -80% exhibit HRS 
[6-11]. Typically cells exhibit low dose hyper-radiosensitivity at doses 
< 0.6Gy above which radioresistance occurs which is maximal beyond 1 Gy. 
The cell survival curve then follows the usual downward bending curve with 
increasing dose.
The cell lines investigated to date include colorectal carcinoma, malignant 
melanoma, bladder carcinoma, prostate adenocarcinoma, lung 
adenocarcinoma, gliomas, neuroblastoma and a number of normal tissue 
cell lines. Figure 1.3 summarises much of the data available to date and 
indicates by the wide diversity of cell lines investigated that LDHRS is 
widespread [6].
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Figure 1.3: The ratio of the survival curve slope measured at very low 
doses (is ) to the slope extrapolated from the high dose response ( r) is 
plotted against high dose radioresistance as indicated by the surviving 
fraction measured at 2Gy. There is a trend for ceil lines that are more high 
dose radioresistant to demonstrate the greatest gain in radiosensitivity as
the dose is reduced to less than 10cGy, but this is not significant [6].
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(8) Fractionated low dose radiation exposure
As well as data on the response of cell lines to single low dose exposures, 
there is a growing amount of data on the response of cell lines to 
fractionated low dose radiation. If LDHRS is to be of relevance clinically 
there must be a hypersensitive response to each fraction of a multi-fraction 
treatment schedule, as, if the effects of low doses are indeed larger than 
predicted by the LQ model then the use of many low dose fractions will 
magnify this difference.
Smith et al [43] studied the effects of fractionated low dose y-rays on both 
C3H 10T1/2 mouse embryo cells and V-79 Chinese hamster cells. The cells 
were exposed to 6Gy of y-rays in fractions of 6Gy, 3Gy, 2Gy, 1Gy or 0.3Gy 
with time intervals of 3 hrs. The results from the two cell lines were virtually 
identical and were not inconsistent with some hypersensitivity at low doses, 
in that 20 fractions of 0.3Gy produced a slightly lower (though non­
significant) surviving fraction compared with the same dose given in 2Gy 
fractions. However, the results of 0.3Gy x 20 exposures agreed well with the 
standard LQ model predictions based on higher dose per fraction. They 
concluded that there was no evidence of any effects at doses of <1Gy that 
are inconsistent with those predicted by the LQ formula.
This data must be interpreted in the light of a number of issues. Firstly, it 
should be noted that a 3-hour interfraction interval was used, which is 
shorter than that used in other experiments and may not be optimal. 
Secondly, the response of C3H 10T1/2to single low dose exposures had not
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previously been investigated- so the lack of LDHRS following fractionated 
doses could be explained by the fact that LDHRS does not occur at all in 
this cell line. As regards the V79 cell line; although it is known to exhibit 
LDHRS to single low doses, the effect is much smaller than in other cell 
lines.
More recently, Short et al [20] investigated the effects of fractionated low 
dose radiation on four radioresistant glioma cell lines. Of these, three (T98G, 
U87 and A7) had previously exhibited LDHRS to single low doses while the 
fourth U373 had not. Not surprisingly, they found no evidence of LDHRS to 
multiple low doses in the cell line that had not shown it with single low 
doses. In the others they found a lower than predicted cell survival -  
consistent with repeated LDHRS -  when the doses are spaced by certain 
intervals. In the T98G cell line a second hypersensitive response was only 
seen when there was an interval of 2-6 hrs, in U87 cells it needed 1-5 hrs 
and in A7 cells 2-8 hrs.
They concluded that a fractionated course of very low doses produces 
increased cell kill when applied to radioresistant tumour cells in-vitro given 
an appropriate inter-fraction interval and suggested that the same 
phenomenon might occur in-vivo leading to better cell killing in radioresistant 
tumours. See Figure 1.4.
In addition to this, Beauchesne et al [10] compared the effects of 0.8Gy TDS 
(interfraction gap of 4 hrs) with the biologically equivalent dose in 2Gy
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fractions OD on G5, CL35 and G152 glioma cell lines. They reported a 
dramatic decrease in cell survival in G5 and G152 glioma cell lines with the 
“ultrafractionated” regime -  both of these cell lines had previously 
demonstrated a hypersensitive response to single low dose fractions. There 
was no difference between the 2 regimes in the CL35 cell line which was not 
surprising as this cell line had not expressed the LDHRS phenomenon to 
single low doses.
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(C) Low Dose Rate Radiation Exposure
The "Induced Repair" model predicts that this hypersensitivity to radiation at 
low doses would translate into a similar sensitivity when cells are exposed 
continuously to low-dose rate radiation. As with acute single low dose 
exposures, cells exposed to low dose rate radiation continuously will, in 
effect, be receiving very low doses of radiation per unit time. It is assumed, 
therefore, that insufficient damage will be caused to induce activation of 
repair within the irradiated cell. It may even be the case that low dose rate 
exposure is more effective than acute low dose exposure, as greater total 
doses may be given.
There has been a limited amount of investigation into the effects of 
continuous low dose rate exposures on cells. Previous studies have 
demonstrated an inverse dose rate effect at low dose rates on mutation 
induction in both Chinese Hamster V79 cells and on human lymphocytes i.e. 
increased mutagenesis at low dose rate [44,45,46,47]. In addition Colussi et 
al [48] have shown that continuous low dose rate exposure induces larger 
deletions at the human HPRT gene than high dose rate X-rays.
In a recent study Mitchell et al at The Gray Cancer Institute [49] studied and 
compared the effects of low-dose-rate 60Co gamma rays on a number of 
human tumour cell lines in-vitro. Three of these cell lines had previously 
been shown to demonstrate LDHRS (PC3 human prostate cancer & T98G & 
A7 human glioblastomas) and one had been shown to be LDHRS-negative 
(U373 glioblastoma). The LDHRS-positive cell lines demonstrated an
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inverse dose-rate effect at dose rates <1Gy/h - that is, a decrease in dose 
rate led to an increase in effect per unit dose. This effect was not 
demonstrated by U373. It was therefore postulated that this inverse dose- 
rate effect might be related mechanistically to LDHRS i.e. a threshold effect 
on repair induction occurs at both acute low doses and low dose rate 
radiation.
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1.4.2. LDHRS/IRR in vivo
(A) Animal normal tissue data
There is a body of data to suggest that the in-vitro phenomenon of LDHRS 
may translate directly into increased effectiveness of fractionated 
radiotherapy when given in very small doses. Joiner et al [12,50] 
investigated the effects of very low doses of radiation on mouse skin and 
kidney. Using a “top-up” experimental design they assessed the functional 
end-points of skin erythema and kidney function and demonstrated that 
when the dose per fraction is reduced to below 1Gy, the total dose needed 
to produce equivalent normal tissue damage decreased. Figure 1.5(a) [51] 
shows the total dose required needed to reach full acute skin tolerance in 
mouse skin as a function of the dose per fraction in the range 0.1-5Gy. 
Above 1Gy the data fit that predicted by the LQ model, however at doses 
per fraction of < 0.6Gy, the LQ model significantly underestimates the effect 
of the radiation. Figure 1.5(b) shows a similar response in mouse kidney. A 
similar experiment carried out by Parkins et al [52] demonstrated an 
equivalent effect in mouse lung.
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Further studies on mouse skin contradicted these results however. 
Vegesna et al [53] using wound tensile strength on day 14-post radiation as 
the end-point found no evidence of enhanced radiosensitivity to doses as 
low as 0.1 Gy. This result appears to be supported in a study by Tzaphlidou 
et al [54]. Using electron microscopy they assessed the effects of doses of 
0.5Gy, 1Gy and 2.5Gy on mouse skin collagen at 1, 4 and 8 weeks and 
noted no alterations in collagen. It may be that the doses used were not low 
enough - in previous positive studies LDHRS was only seen at doses < 
0.5Gy.
Recent studies looking at the effect of fractionated low dose radiation on the 
skin of NMRI nude mice suggest the presence of LDHRS at very low doses. 
Using alterations in basal cell density (BCD) as the end-point Dorner et al 
initiated 2 separate studies [55]. The first compared 0.4Gy TDS (inter­
fraction interval -  4 hours) x 6 weeks (7 days/week) with 1,68Gy OD x 6 
weeks (5 days/week) - both regimes therefore received the same total dose 
(50.4Gy) in the same time period. Biopsies were taken on days 0, 4, 7, 14, 
21 and 28 and assessed for changes in BCD. There was no difference 
between the 2 arms in this study. However, the second study compared 
1.2Gy OD x 6/week with 0.2Gy x 6 per day (inter-fraction interval -  4 hours) 
to a total dose of 7.2Gy. Biopsies were taken on days 0, 2, 4 and 6 and 
once again assessed for changes in BCD. This showed a significant 
difference in basal cell density in favour of the low dose per fraction arm. 
They concluded that LDHRS could be demonstrated in the skin of nude 
mice following doses per fraction of 0.2Gy.
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In any clinical trial studying altered fractionation regimens, the spinal cord is 
usually regarded as the critical organ with a tolerance of 48Gy when given in 
2Gy fractions once daily. Obviously if LDHRS exists in normal spinal cord 
then using lower doses per fraction might result in a lowered tolerance dose. 
Ang et al [56] studied the effects of doses <1Gy on rat spinal cord and found 
that less sparing than predicted by the LQ model occurred when lower 
doses were given. Initially it was felt that this may be a manifestation of 
LDHRS, but it has since been interpreted as being due to the short (4hrs) 
interfraction interval used.
In another study involving rat spinal cord, Wong et al [57] concluded that the 
standard LQ model underestimated the sparing effect of low doses per 
fraction provided that sufficient time is left between fractions to allow for 
sublethal damage repair. They went so far as to suggest that cases of 
radiation myelopathy that occurred in patients undergoing altered 
fractionation regimes were due to the short interfraction times used. 
Therefore, from the above data it can be said that there appears to evidence 
to suggest the existence of LDHRS in animal skin, lung and kidney but not in 
neural tissue.
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(B) Animal tumour model data
There have been a small number of studies looking at tumour responses to 
low doses of radiation in-vivo. Beck-Bornholdt et al [58] studied the effects of 
a number of different fractionation regimens on the R1H rat 
rhabdomyosarcoma xenograft model. Tumours were irradiated under 
ambient conditions to receive a total dose of 60Gy in 6 weeks. There were 5 
different fractionation regimens studied -  10Gy once weekly (6 fractions), 
2.85Gy three times a week (21 fractions), 2Gy five times a week (30 
fractions), 1.42Gy per day (42 fractions) and 0.476Gy TDS (126 fractions). 
There was a substantial net growth delay in the 6 and 126 fraction arms, 
with the others being similar to one another but less effective. The net 
growth delay per gray was larger for the hyperfractionated, 126-fraction 
regimen, but there was no dependence on fraction number in the other 
regimens. This increased effect of multiple doses may be due to the 
induction of partial synchrony due to selective killing of cells in different cell 
cycle phases, a reduction in the effect of hypoxia because of the increasing 
number of fractions, or low-dose hypersensitivity.
Short [59] studied the effects of 2 radiation dose regimens on a T98G glioma 
tumour xenograft in nude mice. T98G is a cell line that has demonstrated 
LDHRS to both single fraction and multiple low dose fractions in cell survival 
assays. A total dose of 36Gy was given -  0.4Gy TDS for 30 days 
(interfraction interval of 6hrs) and 1.2Gy OD for 30 days -  and tumour 
measurements were made twice weekly during treatment and for 60 days
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after it. This time represents approximately 60 cell-cycle times, double that
9necessary to produce a 1g tumour (10 cells) assuming one surviving cell at 
the end of irradiation. The mean growth delay after 36 Gy given in 0.4 Gy 
fractions was 313.68 days, and after 1.2 Gy was 138.39 days. This growth 
delay did not reach statistical significance. Figure 1.6 demonstrates a trend 
for increased recurrence free survival for the low dose group but this also 
did not achieve statistical significance. This study was compromised 
because of a high infection rate, which meant that fewer animals than 
planned could be evaluated reducing statistical power.
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Beauchesne et al [10], in a follow-up experiment to that quoted previously, 
compared the effects of 0.8Gy TDS (interfraction gap of 4 hours) with the 
same biologically equivalent dose in 2Gy fractions OD on a G152 glioma 
xenograft. They found that tumour re-growth rate in the mice treated with the 
“ultrafractionated” regime was half that in the mice treated conventionally 
(p<0.05). They concluded that treatment of grafted glioma tumours with 
repeated low dose radiation results in a strong inhibition of tumour growth 
compared to a classical irradiation scheme and went so far as to suggest 
initiation of a clinical study using an “ultrafractionated” regime in the 
treatment of malignant gliomas.
Conversely, Krause et al [60] studied the effects of an “ultrafractionated” 
regime on an A7 glioma xenograft in nude mice. They compared 1.68Gy OD 
X 30 fractions with 0.4Gy TDS X 6 weeks. Both arms received the same 
total dose (50.4Gy) in the same treatment time (6 weeks). “Top-up” doses 
were given in both treatment arms at 2 weeks, 4 weeks and 6 weeks. The 
results, in both the ”top-up” and non “top-up” experiments, demonstrated a 
significant improvement in local tumour control in the conventionally treated 
tumours (p<0.05). It should be noted, however, that although the A7 cell line 
has been shown to demonstrate LDHRS to single fraction low doses, the 
effect following multiple fractionated low dose exposures was much smaller 
than would be expected from extrapolation from the single fraction data. 
This experiment was carried out prior to information being available on the 
effect of cell cycle on LDHRS [S. Short, personal communication]. This 
experiment is currently being repeated using T98G glioma xenografts;
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preliminary results appear to be similar to A7 study [M. Baumann, personal 
communication].
There is, therefore, some evidence to support the existence of LDHRS/IRR 
in vivo, and that the in-vitro hypersensitivity translates into an enhanced 
effectiveness of fractionated radiotherapy when it is given in very small 
fractions. This is exactly what would be expected from the cell line data and 
it also implies a rapid recovery from the adaptive resistance. This means 
that LDHRS may be exploitable clinically. If multiple small (~0.5Gy) doses 
were given, a regimen termed "ultrafractionation"; it may result in an 
enhanced therapeutic ratio. Obtaining an enhanced therapeutic ratio for 
ultrafractionation would be dependent on the tumour cells demonstrating 
more excess sensitivity than the surrounding critical normal tissues. This 
amount of increased sensitivity is dependent not only on the value
ocsen/ocres, but also on rate at which ccres becomes ccsen with decreasing
dose. Looking at the “worst case scenario” normal tissue investigated to 
date, mouse kidney (Joiner [51]), and comparing it with T98G glioma line 
(Short [59]) it can be calculated that 141 fractions of 0.5Gy to a total dose of 
70.5Gy translates into 60Gy in 2Gy fractions to the normal tissue and 117Gy 
in 2Gy fractions to the tumour - a therapeutic gain of nearly 200%.
Clinically, if this effect were real and present in irradiated tissues, it may be 
of considerable significance as often critical normal tissues receive doses 
of~0.5Gy [61]. Additionally, if radioresistant tumours and normal tissues 
demonstrated differing level of LDHRS then this could be exploitable in the 
clinic
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1.4.3. LDHRS/IRR in human normal tissues
Despite the evidence demonstrating LDHRS/IRR in vitro and in vivo there 
has been very little clinical data published. The erythematous response of 
normal human skin has in the past proven useful for testing the predictions 
of the LQ model. In a clinical study Hamilton et al [62] used reflectance 
spectrophotometry to assess skin erythema in response to exposure to 
radiation. They assessed the response to doses ranging from 0.4Gy to 
5.2Gy per fraction and found that the non-visual erythematous reaction was 
greater than expected for the low doses per fraction compared with the 
higher doses. They concluded that either the standard LQ model does not 
apply for low doses per fraction in human skin or that erythema is not 
exclusively initiated by radiation damage to the basal cell layer.
In a clinical study by Turesson et al [6] the dose response in normal human 
skin to low doses per fraction was studied. They studied patients receiving 
standard radiotherapy for prostate carcinoma who consented to multiple skin 
biopsies during the course of the treatment, application of 5mm of bolus to 
the left lateral portal ensured that the dose per fraction was <1Gy. In the 
study, 3mm skin biopsies were taken before and regularly during a course of 
radiotherapy (70Gy in 35 fractions using 11 or 15 MV photons) from 
opposed lateral fields, with 5mm bolus on the left, and at 1.5 and 3 cm 
outside the fields. This allowed assessment of the effects of skin doses of 
0.07, 0.2, 0.45 and 1.1 Gy per fraction. The end points were epidermal basal 
cell density and Ki67 index. The mean dose responses for basal cell density
53
for doses of 0.45 and 1.1 Gy per fraction in 40 patients were compared and 
showed a significant reverse fractionation effect. See figure 1.7.
It was felt that the confounding effect of repopulation would lead to 
misinterpretation of these results, but in both arms the Ki67 index was 
effected in a similar fashion -there was depression during the first 3 weeks 
followed by a significant increase over the following 4 weeks. They 
suggested that repopulation might actually be obscuring the effect of 
LDHRS/IRR.
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Figure 1.7: Dose response for basal ceil density in skin, following daily 
fractions of 0.45 and 1.10 Gy. Mean values and 95% confidence intervals 
are shown for 40 patients. The difference in radiosensitivity, termed "Dose 
Modifying Factor" (DMF) is highly significant [6].
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In a similar clinical study at Mount Vernon, Shah et al [63] investigated the 
response of human skin to low doses of radiation. 24 patients undergoing 
standard radiotherapy for prostate cancer were assessed. Without 
modification the dose to the skin on the lateral portals is in the range 0.3- 
0.5Gy and application of 5mm of bolus to one lateral portal increases the 
dose on that side to >1Gy per fraction. Skin biopsies were taken prior to and 
during radiotherapy and assessed for changes in basal cell density.
A plot of BCD versus skin dose demonstrated a significant reduction in cell 
numbers for the low dose side, which was about twice that of the higher 
dose side. The results of this study were in complete accordance with those 
of Turesson et al and pointed towards the existence of LDHRS/IRR in 
normal skin. See figure 1.8
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Figure 1.8: Dose response for basal cell density in skin following daily 
fractions of 0.45Gy and 1.1Gy.The right hip received ~1.1Gy per fraction 
and the left hip ~0.45Gy per fraction. An “enhancement ratio” of 2.03 was 
seen (95% Cl 0.8-2.28) [63].
Clinical evidence of LDHRS/IRR has also been suggested in a study by 
Lambin et al [6]. 21 patients with a primary head and neck tumour treated 
with radiation therapy were assessed for alterations in salivary gland 
function in relation to radiation dose. The patients had CT and salivary gland 
scintigraphy (SGS) with free 99mTcpertechnetate performed prior to and 1 
month following completion of radiotherapy. Six of the patients had a large 
gradient of doses in their parotid allowing assessment of doses per fraction 
of 0.57 Gy or less. Dose-response curves were constructed based on the 
dosimetric CT and the decrease of parotid function as assessed by 
scintigraphy before and after radiation. These dose-response curves 
demonstrated some evidence of hypersensitivity at low doses per fraction. 
See Figure 1.9.
58
200
150 r Pose/Fr
- 0.2 0.4 Gy
^  100
Q .
H —
6040 50300 10 20
Total dose in 25 fractions (Gy)
Fig 1.9: Dose - response of parotid gland of one patient. The Y-axis shows 
the loss of function of the parotid after irradiation, computed as the 
difference between the salivary excretion fraction before and one-month 
after irradiation (Delta SEF). The X-axis shows the radiation dose; each 
slice of 5 mm of the parotid has been irradiated at various total doses in a 
fixed number of 25 fractions, therefore 10 Gy corresponds to a dose per 
fraction of 0.4 Gy. The fit to the data is linear except at the 2 lowest doses, 
which demonstrate increased radiosensitivity. Data points are mean ± SD 
[6]-
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1.5. Skin as a Model of Normal Tissue
Numerous studies have been carried out assessing the radiation response 
of normal skin. There are a number of reasons for this - skin lies in the 
primary radiotherapy field more frequently than any other normal tissue, it is 
readily observable and the early and late reactions, at doses above 
1 Gy/fraction following radiotherapy have been well documented. Although it 
may not always represent the critical dose limiting normal tissue for 
radiotherapy, knowledge of its response is important for modelling other 
acute reacting tissues. Thus, the choice of skin as the organ of interest for 
the assessment of normal tissue response allows correlation with historical 
data and forms the basis of analysis of other normal tissues for LDHRS. The 
evaluation of epidermal basal cell density in the study of the biological 
effects of ionising radiation is well documented [64-67].
1.5.1 Structure of Human Epidermis
The skin is one of the major organs of the body constituting about 3% of the 
total body weight. One of its major functions is to provide a physical barrier 
to protect the body against the hazards of the environment. It controls liquid 
and electrolyte loss and also protects against infection. These functions 
have been shown to be of vital importance if the barrier is breached as a 
result of ionising radiation. The skin is also important in thermoregulation, 
detection of sensory stimuli, synthesis of vitamin D and is an integral part of 
the body’s immune system.
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The skin is composed of multiple layers, which can be grouped into two 
main structures: the outermost layers are referred to collectively as the 
epidermis and are derived from the embryonic ectoderm. The deeper layers, 
which are of mesenchymal origin, comprise the dermis. The dermis is 
infiltrated by specialised structures, the skin appendages, which are formed 
by an infolding of the epidermis. It is the epidermis that is of relevance to this 
study. See figure 1.10
The epidermis is a keratinised stratified squamous epithelium subdivided 
into several clearly defined layers; the stratum basale, stratum spinosum, 
stratum granulosum and stratum corneum. The cell kinetic organisation of 
the epidermis fits that of a steady state self-renewing tissue with hierarchical 
organisation (type H tissue) of stem cells, transit cells and functional end 
cells [68]. The outermost layer the stratum corneum is made up of flattened 
dead cells to form approximately 25% of the thickness of the epidermis 
[69,70]. The stratum granulosum lies beneath the non-viable stratum 
corneum [71]. Organelles are gradually lost from cells in this layer, the cells 
become flattened and eventually the nucleus degenerates. The main viable 
layers of the epidermis lie beneath the stratum granulosum. Their structural 
and proliferative organisation determine the response of the epidermis to 
radiation-induced injury. The upper layer of the viable epidermis, the 
stratum spinosum, is largely composed of post-mitotic cells. Cell division is 
to a large extent, but not exclusively, found in the basal layer of the 
epidermis. It is assumed that about 10% of the cells found in the basal layer
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are stem cells. Other cell lines found at the basal layer include 
keratinocytes, Langerhans cells and melanocytes.
The sites of potential stem cells have been widely studied. Earlier studies 
using morphological criteria and radiolabelled thymidine uptake suggested a 
regular distribution of the stem cells along the basement membrane. 
Immunocytochemical studies with putative stem cell markers [72-75] 
demonstrate an irregular distribution of integrin positive cells along the tips 
of the dermal papillae and in the “bulb” region of the hair follicle. This has 
implications for studying the response of the epidermis to radiation from low 
energy X-rays, beta and alpha emitters in which there may be a 
considerable dose inhomogeneity complicating the assessment of specific 
cell types.
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tFigure 1.10: Skin at high power (X400). A= Stratum Corneum, B= Stratum
lucidum, C= Stratum Granulosum, D= Stratum spinosum, E= Stratum 
Basale, F= Dermo-epidermal junction, G= papillary dermis, H= Reticular
dermis.
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1.5.2 Epidermal organisation and kinetics
The epidermis has been classically viewed as stratified squamous 
epithelium maintained by cell division within the basal cell layer, which is 
attached to the epidermal basement membrane.
Keratinocyte stem cells must give rise to all epidermal cell layers, but the 
majority of cells in epidermis are committed to terminal differentiation [76]. A 
transit amplifying population of epidermal keratinocytes can undergo a 
variable number of rounds of cell division before becoming postmitotic. 
Kinetic analysis of mouse epidermis using radioactive thymidine label 
retaining cells demonstrates that 10% of cells can form new foci of 
epidermis (stem cells) [77]. In vitro, there is heterogenous expression of p1 
integrin for basal keratinocytes; basal cells expressing higher levels of p1 
integrin show rapid adhesion to collagenous substrates, have a high colony 
forming efficiency and contain 45% of cells retaining tritiated thymidine, a 
potential stem cell marker. This suggests that p1-integrin bright cells 
contain the stem cell population. Recent work suggests these cells are 
located in the interfollicular epidermis and in a bulge region of the hair follicle 
[75],
Transit amplifying cells and postmitotic keratinocytes occur in the basal 
layer, but suprabasal keratinocytes can also undergo cell division, although 
committed to differentiation. It has been shown that 30% of cells undergoing 
DNA synthesis are above the basal cell layer [78]. Potten has suggested
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that discrete “epidermal proliferative units” exist each with a stem cell 
surrounded by transit amplifying cells and postmitotic cells, and associated 
Langherhans and melanocytic cells. However, this organisation has been 
disputed in human skin studies as cited above.
Epidermal kinetics are complicated by the balance between growth, 
differentiation and cell death. The turnover time in skin is the time for the 
whole population to replace itself and depends on the cell cycle time and the 
growth fraction. The cell cycle or intermitotic time represents the interval 
between two successive mitoses. See figure 1.11. The growth fraction is 
the proportion of basal cells that are proliferative at any one time. The 
mitotic index of the basal layer is the fraction of basal cells that is in mitosis 
at any point, and the labelling index is the fraction of basal cells in DNA 
synthesis.
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Figure 1.11: Diagrammatic representation of the cell cycle
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These parameters have been summarised in the table below. Table 1.1.
s
Perturbations from the resting state will result in significant changes in 
epidermal kinetics. This may be a physiological response e.g. to radiation or 
a pathological process e.g. psoriasis.
Cell kinetic parameter Human data
Mitotic index (%) 0.2-0.4
Labelling index (%) 4.3-8.1
Duration of mitosis, Tm (hours) 1.0-1.5
Duration of DNA synthesis, Ts (hour 9.7-10.6
Cell production rate, k (cells/1000 cell 5.1-8.8
Turnover time (hours) 120-184
Table 1.1: Epidermal kinetics in man [79].
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1.5.3 The regulation of epidermopoiesis
The control mechanism for maintaining the constant epidermal cell 
production and cell loss consists of a balance of stimulatory and inhibitory 
signals. Stimulatory signals include the epidermal growth factor family of 
human epidermal growth factor, transforming growth factor alpha, 
amphiregulin and keratinocyte growth factor. Inhibitory signals include 
transforming growth factor beta, alpha and gamma interferon and TNF 
alpha.
A number of signal transduction pathways have been postulated to be 
important in the regulation of growth and differentiation in the skin, involving 
growth factors, hormones, cell surface receptors, second messengers and 
their control. These include the adenylate cyclase monophosphate
pathway, protein kinase C, tyrosine kinase, p21-ras, NK kb transcription 
factor and nuclear receptors (steroid, thyroid, vitamin D and retinoic acid).
1.5.4 Terminal differentiation of the epidermis
As the epidermal keratinocytes move through the epidermis they undergo a 
complex process of terminal differentiation to produce the stratum corneum. 
The stratum corneum cells have lost their nuclei and other recognisable 
organelles and comprise 65% insoluble keratin proteins. There is synthesis 
of a highly insoluble cornified envelope derived from involucrin. In addition 
to the formation of keratin proteins and the cornified envelope, there are
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changes in the expression of intracellular lipids, membrane glycoproteins, 
growth factor receptors, intercellular adhesion proteins, cell matrix adhesion 
proteins and blood group antigens [80].
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1.6. The Response of Skin to Ionising Radiation
Knowledge of the dose tolerance and pathophysiology of irradiated skin is 
important.
1.6.1 Pathophysiology
The epidermis represents a constantly renewing, hierarchical type of tissue. 
Cell proliferation occurs in the basal and suprabasal layers [78], having a 
generation time of about 2.6 days. The minimum transit time for a labelled 
basal cell to pass from the basal layer, through the other layers and be shed 
from the corneal layer is about 26 days [81]. Following radiation there is a 
dose dependent reduction in stem cells, which results in a decrease in the 
influx of cells into the transit cell compartment. Pre-existing differentiated 
cells have an unaltered life span and in the absence of further proliferation, 
this would result in thinning of the epidermis with flattening of the papillae. If 
the entire differentiated population of epidermal cells is lost before a new 
transit cell compartment is re-established from a sufficient number of stem 
cells then loss of the skin surface will occur. Within a few days of irradiation 
there is a marked fall in the thymidine labelling index and the mitotic index of 
basal cells [82]. In pig skin [65], the rate of cell loss has been shown to be 
2.6% per day after both single and fractionated irradiation. This rate of cell 
loss is independent of the final radiation dose [65], and also the time to the 
appearance of the early reaction and its rate of increase as they are related
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to cell loss, which continues at the pre-irradiated rate. The peak reaction 
and degeneration are related to the dose - as they relate to the proportion of 
surviving stem cells. Following radiation repopulation of the basal layer 
occurs from proliferation of surviving stem cells within the irradiated volume, 
from cells at the periphery of the irradiated volume, and from the hair follicle 
regions [69].
A review by Archambeau et al [81] in 1995 summarised the effects of 
different radiation doses per fraction on skin as follows. Following a large 
single fraction of radiation, there is a linear loss of basal cells which reaches 
a nadir at ~21 days, this is followed by an exponential recovery which leads 
to control levels being reached at 28-32 days. The mitotic and labelling 
indices are increased during this period. Complete regeneration can be 
produced following all doses up to ~45Gy.
When assessing epidermal basal cell density following fractionated radiation 
exposure (2Gy/fraction), there is no alteration in BCD until doses in the 
range 20-25Gy have been given. This is followed by a period of cell loss 
which is maximal at ~50Gy, but which returns to control levels at ~60Gy due 
to cellular proliferation occurring during continuing irradiation
These models suggest that the rate of reduction in basal cell density 
following exposure to radiation is independent of dose given, and cell loss 
occurs at a rate equivalent to it’s natural turnover time i.e. in the absence of 
proliferation, differentiation and cell loss will continue at the same rate.
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1.6.2 Clinical Syndromes
Following radiation exposure, the changes in skin follow a reproducible 
pattern that is dose dependent.
Early skin changes
These occur during the first 70 days following radiation of up to 20Gy in a 
single exposure or up to 60Gy as a fractionated course. The initial feature is 
erythema, which is followed by pigmentation, epilation and desquamation. 
Moist desquamation may occur if the dose is large enough, which will either 
heal by 50 days or proceed to ulceration and necrosis.
Late skin changes
These tend to occur at >10 weeks following radiation and are characterised 
by atrophy leading to contraction of the irradiated area and the appearance 
of induration or "radiation fibrosis".
The development of telangiectasia after 1 year demonstrates the 
progression of vascular injury to the dermis.
1.6.3 The Response of Skin to Low-Dose per Fraction Radiation
As previously stated, to date there has been a limited amount of 
investigation into the effects of low doses of radiation on normal human 
tissues. Three studies have focused on the effects of low doses per fraction 
on skin. In the first Hamilton et al [62] used human skin erythema as an
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endpoint and concluded that the LQ model significantly underestimated 
peak erythema values at doses of <1.5Gy/fraction. In a later study Turesson 
et al [6] compared the effects of a range of doses per fraction on basal cell 
density (BCD) in human epidermis and demonstrated that when doses of 
0.45Gy/fraction were compared with doses of 1.1 Gy/fraction, there was a 
significant reverse fractionation effect in favour of the lower dose per fraction 
regime. Using a very similar technique Shah [63] compared doses of ~0.5Gy 
with ~1Gy and once again demonstrated greater cell kill per unit dose in the 
lower dose per fraction regime.
In summary, the patho-pysiological response of skin to ionising radiation has 
been extensively investigated. Descriptive studies focus on the 
development of skin reactions as a whole organ and are generally unable to 
distinguish specific epidermal and dermal contributions. Additional 
knowledge from the use of different doses and penetrative powers of 
ionising radiations combined with histological evaluation allows a fuller 
understanding of epidermal and dermal behaviour. This study assesses the 
response of the basal cell layer in isolation against the background 
knowledge of the complex cellular and functional interactions of skin 
subdivisions.
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1.7. Conclusion
The LQ model adequately describes cellular response to ionising radiation 
at doses above ~1Gy. In the past it was difficult to accurately assess cell 
killing by ionising radiation below this dose. This has now been overcome by 
the development of the Fluorescent-Activator-Cell-Sorter (FACS) and the 
Dynamic Imaging Processing Scanner (DMIPS). Using this technology it has 
been shown that many cell types exhibit hypersensitivity to doses of less 
than 1Gy.
It has been proposed that this hypersensitivity might be exploitable clinically 
if it is practical to deliver radiotherapy as a very large number of very small 
(<0.5Gy). If some tumour types are found to exhibit enhanced 
radiosensitivity at low doses, the use of low doses to exploit hypersensitivity 
may be a way of improving local tumour control by overcoming 
radioresistance. The more effective application of low dose radiotherapy will 
depend eventually on uncovering the mechanisms of LDHRS, which may 
allow exploitation of the phenomenon to enhance tumour killing at all doses. 
An understanding of low-dose effects is also important to the understanding 
of the potentially harmful effects of non-therapeutic exposure to irradiation. 
Improved understanding of low-dose radiation effects might therefore 
influence both the treatment of radioresistant tumours and low-dose risk 
estimation.
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CHAPTER 2: MATERIALS AND METHODS (CLINICAL STUDY)
The existence of LDHRS in tumours in vivo can only be exploited if the 
surrounding normal tissue exhibits lower levels of cell kill or improved 
recovery after fractionated low dose radiotherapy (increased therapeutic 
ratio). This study was designed to investigate the response of tumour and 
normal tissue (skin) to multiple low doses of radiation. Tumours metastatic 
to skin were chosen for a number of reasons, firstly they were easy to plan, 
treat and measure, and secondly direct comparison of the effects of low 
dose radiation could be made with the surrounding normal skin.
The term “ultrafractionation” has been used to define radiotherapy delivered 
at 0.5Gy per fraction in multiple fractions per day; in this study 
“ultrafractionated” radiotherapy was compared to once daily conventional 
radiotherapy.
Ethical approval was granted from Watford and Mount Vernon Hospital NHS 
Trust Ethical Review Committee.
2.1 Study Design
The design of the "ultrafractionated" regime was based on in-vitro data, 
which suggest that 0.4-0.5Gy at 2-6 hour intervals produces repeated 
LDHRS in a number of radioresistant cell lines [20], The total dose and 
overall time were chosen to be comparable to a conventional palliative
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regime, to satisfy the requirements of research and to be acceptable to 
patients.
To make comparison with routine clinical practice we converted the dose 
fractionation schedules to single dose equivalent (gray) using the low-dose 
sensitivity parameter (as), the a/p ratio and the SF2 for a number of tumour 
cell lines (including glioma, melanoma and bladder carcinoma) and for skin 
and kidney. For a total dose of 18Gy given as multiple low dose fractions, 
the single dose equivalent for radioresistant tumour cell lines lies between 
7Gy and 13Gy, which is within the range commonly used for palliation in 
clinical practice. The primary endpoints of the study were threefold: tumour 
growth delay and, in the rim of normal skin included in all treatment fields, 
changes in BCD and the proliferation markers Cyclin A and Ki67.
2.2 Study endpoints
The endpoints of the study were as follows
• Time to re-growth of the tumour nodules in each treatment group.
• Changes in epidermal basal cell density (BCD) in the surrounding normal 
skin in each treatment group, assessed at regular intervals during and after 
radiation.
• Assessment of proliferation (using Ki67 & Cyclin A) in the surrounding 
normal skin, assessed at regular intervals during and after radiation.
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2.3 Patient Selection
8 patients with multiple (>2) metastatic nodules to either skin or the 
subcutaneous tissues and for whom local palliative radiotherapy was 
appropriate were enrolled over a period of 2 years. Diagnoses were 
metastatic malignant melanoma (3 patients), metastatic leiomyosarcoma (2 
patients), metastatic breast cancer (1 patient) and advanced Non-Hodgkin’s 
Lymphoma (NHL) (2 patients).
2.4 Irradiation Technique
Each patient entered into the study was offered accommodation within the 
Cancer Centre (CHART Lodge), with an accompanying person, for the 
duration of the treatment.
The patients were seen 1 week prior to commencement of treatment by the 
treating clinician, the physicist involved in the treatment planning and the 
radiographer involved in treatment set-up. At this time the lesions were 
measured in three dimensions using callipers with millimetre gradients (See 
Figure 2.1) and their volume calculated. They were then numbered 
consecutively according to volume and randomised in matched pairs to 
receive either an ultrafractionated regimen (0.5Gy TDS with a 4-hr gap, over 
12 consecutive days) or a conventionally fractionated regimen (1.5Gy OD 
over 12 consecutive days). A total dose of 18Gy over 12 days was 
prescribed in both treatment schedules.
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The treatment depth for each lesion was individually determined and each 
lesion was then planned and treated using appropriate electron energies to 
encompass the nodule entirely within the 95% isodose. Where necessary 
wax bolus was specifically designed and applied to ensure adequate 
coverage at depth but also ensure maximum dosage at the skin surface. 
(See figure 2.2)
The circumferential margin encompassing each nodule was chosen to allow 
for the electron isodose bowing effect at depth and also to allow for a normal 
skin biopsy to be performed -  this margin was between 1-2cms in all 
patients (See Figure 2.3). The dose received at 0.1mm below the skin 
surface, the average depth for the basal cell layer of the epidermis, was 
verified by black carbon loaded thermoluminescent dosimeters (TLD).
2.5 Statistical Design
2.5.1 Tumour Nodules
A matched pair design was used to maximise the sensitivity of studying a 
relatively small number of lesions. Assuming a 50% difference in relative 
response rates between the two regimes, it was calculated that a total of 29 
paired lesions would be needed to confirm a difference at the 0.05 
significance level. The times to regrowth of individual nodules were 
compared using the Wilcoxon Signed Ranks Test.
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2.5.2 Surrounding Normal Skin - Alterations in Basal Cell Density 
(BCD)
For basal cell density comparisons, the analysis compared the ratio of the 
slopes of the log [basal cell density] versus time relationship for skin 
receiving 0.5Gy per fraction and 1.5Gy per fraction. This was termed the 
“Enhancement ratio (ER).” The null hypothesis was that the enhancement 
ratio was unity, i.e. that there was no difference in the slopes. An ER >1 
implies a greater biological effect for skin exposed to 0.5Gy per fraction 
compared to skin exposed to 1.5Gy per fraction.
The method of calculating the ER was discussed between the prime 
investigator, Prof. Michael Joiner (Radiobiologist) and Prof. Soeren Bentzen 
(Biostatistician). In view of the baseline variability of normal skin BCD, the 
potential interaction of reduction of BCD following irradiation, response to 
dose and repopulation differences, a non-linear analysis of basal cell density 
response to radiation dose was chosen. Although this may not be the most 
ideal assessment, it was felt to be the most logical and practical approach 
as we were trying to determine whether there was a difference in BCD 
slopes between low and high radiation doses. The slope determined from 
non-linear regression analysis was treated as the best fit straight line. The 
comparison of these "best fit" lines then gave an ER for the doses studied.
The dose response relationship was assessed in each patient individually. 
Enhancement ratios were calculated by performing a non-linear regression
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analysis on each set of data (low dose side and high dose side) then 
comparing the fit parameters. The basal cell density at origin (time 0) for 
each side was included as a dose dependent variable, without normalising 
the irradiated data to the original number of cells counted. ER's were 
calculated for each patient with 95% confidence intervals. A significant 
result was recorded if an ER>1 was associated with the lower confidence 
interval greater than unity or an ER<1 was associated with the upper 
confidence interval less than unity. In some patients, the software was 
unable to determine confidence intervals and ER was coded as 
indeterminate significance. The data were also analysed collectively to 
assess the overall estimated enhancement ratio for low doses per fraction.
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2.6 Assessment of tumour growth delay
Tumour growth delay was assessed by tri-dimensional measurements of 
each nodule prior to treatment, during treatment on days 5, 8 & 12, on day 
26 and then monthly until re-growth occurred. Measurement of nodules 
ceased when they reached, or exceeded their original volume.
The tumour volumes were derived from the formula - 
Volume = length x width x depth x 7i/6
Tumour volumes were then normalised to those on day 0 and plotted 
against time, in days, from the start of treatment. These data were then test- 
fitted to each of three different polynomial functions of degrees 1, 2 and 3 
using least-squares non-linear regression (SAS JMP v4.0). The polynomial, 
which produced the best fit, i.e., the one with the smallest root mean square 
error (RMSE) was selected and/or which fitted the data best on visual 
inspection was selected. The equation of the fitted polynomial was then 
solved to give the number of days for the tumour to reach the starting 
volume. The mean number of data points used to fit the line was 9 (range 7- 
13).
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2.7 Assessment of epidermal basal cell density (BCD)
Human skin biopsies for basal cell evaluation were obtained using a 2 or 
3mm punch biopsy (Terumo - See Figure 2.4), similar to the Nyman 
technique [67]. Local anaesthetic (0.5-1 ml lignocaine 1% ± 2% adrenaline) 
was infiltrated subcutaneously prior a single punch biopsy performed 
perpendicular to the skin surface. The skin defect was then covered with a 
standard medical plaster. Due to concerns regarding stimulation of 
proliferation by skin stripping [83], patients in the study had dry, non­
adhesive gauze applied to the tissue defect thus eliminating any effect of 
skin stripping. The biopsy tissue was fixed in 4% formalin, embedded in 
paraffin, cut into 3um sections and stained in haematoxylin-eosin and PAS 
(periodic acid schiff). Basal cells were manually counted at high power 
(X400). Only the interfollicular epidermis was assessed and any 
melanocytes present were excluded from the count. The length of the 
basement membrane was determined on images captured using an 
Axioscope trans-illumination microscope (Zeiss) connected to a 3 CCD 
colour camera (JVC) connected to a 600MHz Pentium desktop PC with a 
Matrox Meteor frame grabber in a PCI bus. The length was measured using 
a calibrated line tool using standard image analysis routines (Visilog 5.02, 
Noesis Vision, Inc). The basal cell density was calculated as the number of 
basal cells divided by the length of basement membrane assessed 
(cells/mm). See Figure 2.5. The principle investigator (JH) performed 
manual counting of the specimens.
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Number of images captured
For each punch skin biopsy, a minimum of 3 sections were captured at high 
power. Each section would give rise to eight to ten images from which the 
basal cell density was calculated. This results in twenty four to thirty high 
power images captured for each skin biopsy.
2.8 Immunohistochemistry and assessment of proliferative index
Immunohistochemical analysis of the skin was carried by staining for the 
proliferation markers Ki67 and Cyclin A.
2.81 Ki67
Ki67 is a mouse monoclonal antibody that identifies a nuclear antigen 
associated with the cell cycle [84]. Detailed cell cycle analyses has shown 
that the Ki67 antigen is tightly associated with proliferation, being expressed 
at all phases of the cell cycle except GO [85]. It has been demonstrated by a 
number of authors that the amount of Ki67 antigen varies through the cell 
cycle, reaching a maximum during G2 and M phases [86,87].
The function of Ki67 is not completely understood, but it is generally 
accepted that it is an absolute requirement for the maintenance of the cell 
cycle and is essential for cellular proliferation [85].
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Numerous studies have shown a good correlation between Ki67 
immunoreactivity and other indices of cellular proliferation e.g. flow 
cytometry [88-90], thymidine labelling [88, 91-93] and bromodeoxyuridine 
incorporation [91,94,95].
Ki67 is a widely accepted measure of the growth fraction (GF) i.e. the 
actively proliferating cell pool [85,96], Although some authors have stated 
that the fraction of cells showing Ki67 immunoreactivity may overestimate 
the growth fraction in tumours [97] it is accepted to be representative in 
normal tissues [96]
2.8.2 Cyclin A (CyA)
Cyclin A (CyA) is also a marker of proliferation, a member of the "mitotic" or 
"G2 Cyclin" family, and is involved in the control of G2/M and mitosis. It binds 
to and activates cyclin dependent kinase 2 (CDK-2), essential for initiation 
and progression through S phase. Cyclin A is responsible for the progression 
of cells through S-phase and the transition between G2 and M phases 
[98,99] and is expressed after the restriction point in G1, i.e. in S, G2/M and 
the early part of M [99].
2.8.3 Cyclin A: Ki67 Ratio
The Cyclin A: Ki-67 ratio was assessed at each time point as a surrogate for 
accelerated repopulation. It was taken as being representative of the number 
of cells occupying S and G2 phase in the growth fraction.
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To assess each of these indices, de-paraffinised samples were put into a 
plastic rack and placed in a trough containing 250 mils of 10mM citric acid 
(pH adjusted to 6.0 using 2M sodium chloride). The lid was then put on and 
the trough put into a microwave at 750W where three, 4-minute pulses were 
given at high power. The trough was then left to stand at room temperature 
for 10 minutes.
The slides were then washed well in running tap water and rinsed in Tris 
buffer saline (TBS), drained and the section circled with a resin pen. DAKO 
Monoclonal Mouse Anti-Human Ki67 Antigen, used in a dilution range 1:75 -  
1:150, and CASTRA Cyclin A mouse monoclonal antibody, diluted to 1:50 -  
1:100, were then applied. The slides were then washed 3 times in TBS 
(3mins) and biotinylated anti-mouse antibody, diluted 1/4000, was applied for 
1 hour. They were then washed a further 3 times in TBS (3mins) and AB 
Complex/Strept AB Complex was applied for a further hour. Following a 
further wash in TBS (3 x 3mins) Diaminobenzadine (DAB) solution was 
applied for 5mins. Then the sections were rinsed in distilled water, washed 
well under a running tap and the nuclei counterstained with Gills number 1 
Haematoxylin for 60 seconds. They were then washed again, dehydrated 
and mounted in DPX.
For each punch skin biopsy, at least 3 sections were captured at high power 
for assessment of proliferative index. Each section would give five to eight 
images from which the Ki67 and Cyclin A indices were calculated. This
85
results in fifteen to twenty four high power images captured for each skin 
biopsy. The stained slides were analysed at high power with manual image 
counting. The total number of cells in the basal compartment were counted: 
this included both the basal layer and first supra-basal layer as at it is known 
that at least 30% of proliferation occurs in the suprabasal layers [78]. Then 
the number of basal cells that had clear-cut and strong nuclear staining for 
Ki67 and Cyclin A were counted. The indices of Ki67 and Cyclin A were 
calculated by dividing the number of stained cells by the total number of cells 
in the basal cell compartment. See Figure 2.6.
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Figure 2.1: Metastatic skin nodules on the ankle of a patient with 
advanced malignant melanoma
87
Figure 2.2: Calliper measurement of metastatic nodule to skin in a patient 
with advanced NHL
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Figure 2.3: Schematic representation of electron isodose curves 
encompassing a metastatic tumour in skin. Application of wax bolus 
ensures that the nodule is encompassed by the 95% isodose.
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Figure 2.4: Metastatic skin nodules (sarcoma), treatment fields 
demonstrated by blue rings. Rim of normal skin included in treatment 
fields.
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Figure 2.5: Metastatic skin nodules in a patient with advanced breast 
cancer. Blue rings demonstrate treatment fields. Rim of normal skin 
included in treatment fields.
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Figure 2.6. Terumo 3-mm punch biopsy needle
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Cell count 39 
Length 390um
Figure 2.7. High power view of skin biopsy.
Cell count is 39; length measurement is 390 micrometers. Basal Cell 
Density (BCD) is calculated as 100 cells/mm.
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*Figure 2.8: A. High power (X400) view of the proliferation marker Ki67.
B. High power (X400) view of the proliferation marker Cyclin A.
Cells with clear-cut and strong nuclear staining counted as positive. They 
are arrowed.
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CHAPTER 3: RESULTS OF TUMOUR NODULE STUDY
3.1. Assessment of tumour nodule growth delay
8 patients were enrolled over a 2-year period (3M: 5F) with a median age of 
71 years (range 64-81). Diagnoses included metastatic sarcoma (2 
patients), metastatic breast cancer (1 patient), advanced NHL (2 patients) 
and advanced malignant melanoma (3 patients).
A total of 40 paired nodules with a median volume of 0.73cm3 (range 
0.007cm3 to 114.0 cm3) were analysed. 26 of these nodules were derived 
from tumours generally considered to be radioresistant and in which LDHRS 
has been demonstrated in vitro (melanoma and sarcoma - patients 1,3,6,7 & 
8), 10 were in tumours likely to be radiosensitive (NHL - patients 2 & 5) and 
4 were in breast cancer (patient 4), a relatively radiosensitive solid tumour. 
36 nodules have regrown after a median follow-up of 226.5 days (range 76 - 
501 days). 4 nodules have not regrown after >500 days, these were all in a 
patient with NHL (patient 5). See Table 3. 41 & Figures 3.1-3.7.
Analysis of all regrowth data demonstrates a trend towards greater tumour 
growth delay in the nodules treated with the "ultrafractionated" regime (2- 
tailed p-value 0.14) as shown in Figure 3.8. If the data are re-analysed 
excluding the lymphoma nodules, that is leaving metastatic breast cancer 
nodules in addition to the melanoma and sarcoma nodules (30 nodules in 
total) the resultant difference in time to tumour regrowth is statistically 
significant in favour of the low dose per fraction group (P<0.05). Equally
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when the radioresistant tumour nodules of types known to show LDHRS 
were analysed separately (melanoma and sarcoma, 26/26 regrown) a 
statistically significant tumour growth delay in favour of the 
"ultrafractionated" treatment group was demonstrated (2-tailed p-value 
0.009), shown in Figure 3.9.
Within this group there is an apparent difference between sarcoma and 
melanoma nodules. Paired nodules 1-4 represent metastatic sarcoma 
nodules and the mean fractional difference in growth delay for the 
ultrafractionated group versus the conventionally treated group is 24% 
(range 11% to 45%). Melanoma nodules are represented by paired nodules 
5-13 and in this group the mean fractional difference in growth delay is 11% 
(range -28% to +45%).
In 5 of the 18 treated paired nodules "ultrafractionation" decreased tumour 
growth delay. Three of these pairs were NHL; the remaining two pairs were 
breast cancer and melanoma. Figures 3.2, 3.4B & 3.7A.
There would appear to be a difference in volume between those nodules 
treated with “ultrafractionation” and those treated with conventional 
fractionation. If the nodules are ranked according to volume and the 
difference in volume analysed using the Paired Wilcoxon Ranks Test, the 
nodules treated with “ultrafractionation” are significantly greater in volume 
than those treated with conventional fractionation (p=0.002).
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SPECIAL NOTICE
DAMAGED TEXT - INCOMPLETE IMAGE
1 Sarcoma 23 UF 430
17.1 CF 296
2 11.8 UF 462
8.2 CF 373
3 6.0 UF 462
5.24 CF 373
1 NHL 114.0 UF 143
25.6 CF 151
2 15.05 UF 120
2.9 CF 171
3 4.67 UF 120
2.4 CF 171
1 sarcoma 19.0 UF 528
3.15 CF 475
1 breast 0.33 UF 338
cancer 0.23 CF 240
2 0.07 UF 168
0.05 CF 377
1 NHL 7.03 UF No regrowth
2.55 CF No regrowth
2 0.99 UF No regrowth
0.44 CF No regrowth
1 melanoma 1.53 UF 65
6.35 CF 46
1 melanoma 1.7 UF 114
0.7 CF 109
2 0.06 UF 103
0.13 CF 88
3 0.05 UF 126
0.03 CF 105
4 0.05 UF 140
0.015 CF 96
5 0.05 UF 104
0.007 CF 95
1 melanoma 0.07 UF 110
0.015 CF 153
2 0.06 UF 205
0.01 CF 99
3 0.02 UF 205
0.008 CF 105
Table 3.1. Details of treated metastatic tumour nodules and regrowth data. 
UF = "ultrafractionation" and CF = conventional fractionation.
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Figure 3.1 (A-C). Patient 1- metastatic sarcoma. Time to regrowth to original 
volume for 6 paired nodules. Ultrafractionation = dark bars. Conventional
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Figure 3.2(A-C). Patient 2 - advanced NHL. Time to regrowth to original volume 
for 6 paired nodules. Ultrafractionation = dark bars. Conventional fractionation 
= light bars.
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Figure 3.3. Patient 3 • metastatic sarcoma. Time to regrowth to original volume 
for 2 paired nodules. Ultrafractionation = dark bars. Conventional fractionation 
= light bars.
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Figure 3.4 (A & B). Patient 4 - metastatic breast cancer. Time to regrowth to 
original volume for 4 paired nodules. Ultrafractionation = dark bars. 
Conventional fractionation = light bars.
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Figure 3.5. Patient 6 - metastatic malignant melanoma. Time to regrowth to 
original volume for 2 paired nodules. Ultrafractionation = dark bars. 
Conventional fractionation = light bars.
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Figure 3.6 (A-E) Patient 7 ■ metastatic malignant melanoma. Time to regrowth to original 
volume for 10 paired nodules. Ultrafractionation = dark bars. Conventional fractionation 
= light bars.
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Figure 3.7 (A-C). Patient 8 - metastatic malignant melanoma. Time to regrowth 
to original volume for 6 paired nodules.
Ultrafractionation = dark bars. Conventional fractionation = light bars.
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Figure 3.8. Analysis of all nodule data demonstrates a trend towards 
greater tumour control in the "ultrafractionated" group. P = 0.14. UF (dark 
bars): ultrafractionation. CF (light bars): conventional fractionation.
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Figure 3.9. Analysis of sarcoma and melanoma tumour nodules 
demonstrates a statistically significant growth delay in those treated with 
the "ultrafractionated" regime. P = 0.009. UF (dark bars), 
ultrafractionation. CF (light bars) conventional fractionation.
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3.2. Surrounding Normal Skin - Alterations in Basal Cell Density 
(BCD)
Basal cell density (BCD) measurements in skin surrounding metastatic 
tumour nodules irradiated with either 1.5Gy OD or 0.5Gy TDS for 12 
consecutive days were available in 8 patients. This resulted in a total of 
-2000 images being analysed.
There was a significant reverse fractionation effect, i.e. more loss of BCD, in 
the low dose arm in only 1 of 8 patients (patient 4). In this patient the BCD 
versus time relationship showed an enhancement ratio of 3.45 (95% Cl 
indeterminate) and analysis of variance (ANOVA) demonstrated a significant 
reduction in BCD in favour of the low dose arm at day 28 (p<0.05). 
See Table 3.2 & Figure 3.13.
The remaining 7 patients showed no evidence of increased cell loss after 
multiple low doses compared to once daily doses. 1 of these patients 
demonstrated an enhancement ratio of 1.04 (95% Cl 0.66-1.67) suggesting 
that the treatment regimes were equivalent, the remaining 6 patients 
demonstrated enhancement ratios of < 1 suggesting greater cell kill per unit 
dose in the higher dose arm, this reached statistical significance in 4 
patients. See Table 3.2 & Figures 3.10 - 3.12 & 3.14 -3.17.
Analysis of variance of BCD at day 26 in each of these 7 patients showed a 
non-significant reduction in favour of the higher dose arm.
Analysis of the whole patient data set demonstrates an overall enhancement 
ratio of 0.75 (95% Cl 0.61-0.89) See Figures 3.18 & 3.19.
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1 Sarcoma 0.41 0.11-0.698
2 NHL 0.619 0.277-1.019
3 Sarcoma 1.04 0.67-1.67
4 Breast cancer 3.45 indeterminate
5 NHL 0.49 indeterminate
6 Melanoma 0.526 0.315-0.753
7 Melanoma 0.588 0.302-0.911
8 Melanoma 0.477 0.391-0.565
Table 3.2: Patient characteristics, diagnoses and "enhancement ratios" 
from BCD measurements.
A statistically significant result is designated using bold type.
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Figure 3.10. BCD data for patient 1. Multiple low dose radiation exposures 
(0.5Gy TDS x 12 days) (▲) are compared to once daily conventional 
exposures (1.5Gy OD x 12 days) (•). Error bars denote 95% confidence 
limits. "ER" 0.41 (95%CI 0.11-0.698).
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Figure 3.11. BCD data for patient 2. Multiple low dose radiation exposures 
(0.5Gy TDS x 12 days) (▲) are compared to once daily conventional 
exposures (1.5Gy OD x 12 days) (•). Error bars denote 95% confidence 
limits. "ER" 0.619 (95%CI 0.277-1.019).
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Figure 3.12. BCD data for patient 3. Multiple low dose radiation exposures 
(0.5Gy TDS x 12 days) ( A ) are compared to once daily conventional 
exposures (1.5Gy OD x 12 days) (•). Error bars denote 95% confidence 
limits. "ER" 1.04 (95%CI 0.67-1.67).
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Figure 3.13. BCD data for patient 4. Multiple low dose radiation exposures 
(0.5Gy TDS x 12 days) ( A ) are compared to once daily conventional 
exposures (1.5Gy OD x 12 days) (•). Error bars denote 95% confidence 
limits. "ER" 3.45 (95%CI indeterminate).
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Figure 3.14. BCD data for patient 5. Multiple low dose radiation exposures 
(0.5Gy TDS x 12 days) ( A ) are compared to once daily conventional 
exposures (1.5Gy OD x 12 days) (•). Error bars denote 95% confidence
limits. "ER" 0.49 (95%CI indeterminate).
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Figure 3.15. BCD data for patient 6. Multiple low dose radiation exposures 
(0.5Gy TDS x 12 days) ( A ) are compared to once daily conventional 
exposures (1.5Gy OD x 12 days) (•). Error bars denote 95% confidence 
limits. "ER" 0.526 (95%CI 0.315-0.753).
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Figure 3.16. BCD data for patient 7. Multiple low dose radiation exposures 
(0.5Gy TDS x 12 days) (A ) are compared to once daily conventional 
exposures (1.5Gy OD x 12 days) (•). Error bars denote 95% confidence 
limits. "ER" 0.588 (95%CI 0.302-0.911).
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Figure 3.17. BCD data for patient 8. Multiple low dose radiation exposures 
(0.5Gy TDS x 12 days) (▲) are compared to once daily conventional 
exposures (1.5Gy OD x 12 days) (•). Error bars denote 95% confidence
limits. "ER" 0.477 (95%CI 0.391-0.565).
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Figure 3.18. Non-normalised BCD data for all patients. Multiple low dose 
radiation exposures (0.5Gy TDS x 12 days) (A ) are compared to once 
daily conventional exposures (1.5Gy OD x 12 days) (•). Error bars denote 
95% confidence limits. "ER" 0.75 (95%CI 0.61-0.89).
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Figure 3.19. Normalised BCD data for all patients. Multiple low dose 
radiation exposures (0.5Gy TDS x 12 days) ( A ) are compared to once 
daily conventional exposures (1.5Gy OD x 12 days) (•). Error bars denote 
95% confidence limits. "ER" 0.75 (95%CI 0.61-0.89).
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3.3. Surrounding Normal Skin - Alterations in proliferative indices (Ki67 
& Cyclin A)
The mean pre-radiotherapy values of Ki-67 and Cyclin A labelling indices 
were 10.05 ± 0.798 (SE) and 4.81 ± 0.696 (SE) respectively.
Repeated assessment of Ki-67 and Cyclin A following irradiation suggested 
similar responses in both treatment arms. In both schedules the Cyclin A 
and Ki-67 labelling indices (LI) decrease during the first 10 days and then 
increase over the next 2-3 weeks. This pattern of response occurred in all 
patients irrespective of treatment group. When the Ki-67 and Cyclin A were 
analysed collectively for all 8 patients, the decline in labelling Indices 
appeared to be slower in the "ultrafractionated" arm compared with the 
conventional arm and the depression persisted at day 12 whereas the 
conventionally treated skin had started to recover. See Figures 3.20-3.28.
The Cyclin A: Ki-67 ratio was also assessed at each time point. It was used 
as a surrogate for accelerated repopulation as it was taken as being 
representative of the number of cells occupying S and G2 phase in the 
growth fraction. In the untreated (pre-radiation) cells the Cyclin A positive 
fraction is expected to be 30 to 50% of the Ki-67 positive fraction. This value 
in Study 2 was 45.3 ± 3.01 (SE). This ratio increased rapidly in the 
conventionally treated arm, reaching 55% at day 5 and 70% at day 8. The 
increase in the ratio was not quite so marked in the "ultrafractionated" arm, 
but still reached -65% at day 8. At day 26 the ratios were still elevated 
compared to the pre-radiation values in both treatment groups. See Figure 
3.28.
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Figure 3.20. Proliferation data for patient 1. Multiple low dose radiation
exposures (A ) are compared to once daily conventional exposures (•).
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Figure 3.21. Proliferation data for patient 2. Multiple low dose radiation
exposures (A)  are compared to once daily conventional exposures (•).
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Figure 3.22. Proliferation data for patient 3. Multiple low dose radiation
exposures (A)  are compared to once daily conventional exposures (•).
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Figure 3.23. Proliferation data for patient 4. Multiple low dose radiation
exposures (A)  are compared to once daily conventional exposures (•).
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Figure 3.24. Proliferation data for patient 5. Multiple low dose radiation
exposures (A)  are compared to once daily conventional exposures (•).
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Figure 3.25. Proliferation data for patient 6. Multiple low dose radiation
exposures (A)  are compared to once daily conventional exposures (•).
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Figure 3.26. Proliferation data for patient 7. Multiple low dose radiation
exposures (A)  are compared to once daily conventional exposures (•).
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Figure 3.27. Proliferation data for patient 8. Multiple low dose radiation
exposures ( A)  are compared to once daily conventional exposures (•).
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CHAPTER 4: DISCUSSION OF TUMOUR NODULE STUDY
4.1 Tumour Nodules
"Ultrafractionated" radiotherapy using a regimen of 0.5Gy TDS (interfraction 
interval of 4hrs) significantly increased time to tumour regrowth in metastatic 
melanoma and sarcoma tumour nodules (P = 0.009). The fact that analysis 
of all of the nodules in the study did not yield a significant advantage in 
favour of "ultrafractionation" is unsurprising and explained by the fact that 
the group included a number of lymphoma nodules. It is generally accepted 
that lymphomas are exquisitely radiosensitive and therefore by comparison 
with the library of cell lines tested in-vitro, unlikely to show LDHRS.
When the data is analysed without the lymphoma nodules, thus including 
the breast cancer, sarcoma and melanoma nodules, the resultant difference 
in time to tumour regrowth is statistically significant (p<0.05).
Tumour growth delay is a commonly used end point in radiotherapy and 
chemotherapy protocols involving xenograft studies and in phase III 
randomised clinical trials. It is assumed that this is a valid surrogate for 
tumour cell kill, as a reduction in the clonogen population will lead to a delay 
in the tumour doubling time. However, this assumes the increase in size is 
directly related to tumour clonogens and it is known that a tumour mass also 
harbours several host cells (lymphocytes, macrophages, fibroblasts) also 
capable of proliferation and which may be killed by radiation. The tumour
129
regrowth pattern will also depend on the tumour microenvironment, which 
may be host, or tumour derived depending on the conditions of growth of the 
tumour; and tumour regrowth may be influenced by the microenvironment 
independent of which agent is studied. In vivo, a primary tumour and 
metastasis, from the same tumour, may behave differently to the same 
agent as different populations of tumour cells may coexist in different 
proportions at each site. Tumour regrowth, in this situation, may be a 
reflection of the response of a range of tumour cells, which are 
heterogenous. Overall, time to tumour regrowth was felt to be a valid 
endpoint in this study as the lesions studied were relatively small and 
therefore more homogenous, subcutaneous and all metastases. We felt this 
minimised the influence of the above factors and were satisfied that volume 
measurement was suitable in this study. It was also felt to be the most 
practical in this situation where palliative radiation would be standard 
treatment.
There are, however, a number of technical issues that should be addressed. 
The assessment of lesions was performed by tri-dimensional measurement 
using calibrated callipers. Artefactual measurements are known to occur in 
this setting with linear calliper measurements overestimating surface nodule 
size by a median of 23% [100]. In this study, a single investigator performed 
all the readings, which should eliminate interobserver variation. However, 
intraobserver variation could not be assessed as the nodules could not be 
measured blinded and frequent reassessment would have been impractical. 
In this respect, a 23% overestimation in each dimension would be likely to
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have a significant impact when tri-dimensional measurement of surface 
nodules is used. Circumferential loop planimeter measurements may be 
more accurate with a median overestimation of 17% and better 
interobserver and intraobserver variation [100]. This instrument would merit 
further evaluation in the study of multiple cutaneous nodules treated with 
various fractionation schedules.
The patients were treated using electron energy with surface bolus to 
encompass the subcutaneous lesion to appropriate depths. Although the 
Biologically Effective Dose (BED) of electrons has been calculated at around 
0.9, the 10% loss in biological effectiveness is unlikely to affect the outcome 
of the growth delay parameters as all the nodules were treated in a similar 
fashion. The treatment depth of the lesions was calculated to ensure full 
coverage with the 90% isodose contour, with a low probability of a 
geographical miss at depth. The use of surface bolus (wax) to increase the 
skin dose and in some cases, to reduce the depth dose, is unlikely to alter 
the growth behaviour of the nodules in favour of one regime over another.
Therefore, although this study demonstrates a significant increase in time to 
tumour regrowth it does not provide direct evidence of increased clonogenic 
cell killing by low dose fractions. We did not establish cell lines from these 
tumours and hence do not have any in-vitro data to directly support the 
clinical findings. However, the result strongly supports the existence of a 
true hypersensitive response to low doses per fraction in radioresistant 
tumour types clinically and is in accord with what would be expected from
extrapolation of existing in-vitro data in these tumour types. Nevertheless 
alternative explanations should be considered.
One possible alternative hypothesis is that the low dose radiation caused a 
change in the local immune response that differentially affected some 
metastatic tumours. It is well known that low-dose radiotherapy (LD-RT) has 
a significant anti-inflammatory effect and it has been used to treat a variety 
of inflammatory conditions such as rheumatoid arthritis, osteoarthritis, 
abscess and psoriasis [101]. This anti-inflammatory effect is in stark contrast 
to the pro-inflammatory effect seen following higher doses of radiation and is 
most marked in the dose range 0.3-0.6Gy/fraction.
Radiation treatment for benign disease became unpopular in many countries 
following the publication of data showing late harmful side effects [102] and, 
in particular, an epidemiological study of over fourteen thousand patients 
who had been treated for ankylosing spondylitis with radiation in the 1930s 
to 1950s which reported an increased incidence of leukaemia, aplastic 
anaemia and solid tumours in the irradiated organs [103]. However in many 
countries RT is still practised as the treatment of choice for such conditions 
as insertion tendinitis and osteoarthritis [101]. The underlying radiobiological 
mechanisms of this effect are not understood, but cell death and inhibition of 
proliferation as seen during treatments for malignant disease are not 
expected to be involved in the response to these low doses [104]
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One postulate is that it may be partly due to a reduction in the production of 
nitrous oxide (NO) by macrophages [105]. It has been demonstrated that 
low radiation doses have quite different effects on the functional abilities of 
activated macrophages compared with higher doses with doses in the range 
0.6-1.2Gy being most effective at suppressing NO [105]. A reduction in 
oxidative stress [106] and a reduction in adhesion of inflammatory cells to 
endothelial cells [104] have also been implicated.
Taken together, these effects on macrophages, lymphocytes and endothelial 
cells all oppose the inflammatory process and they are all observed in the 
low dose region, which correlates closely with clinical experience of anti­
inflammatory effects. Schaue et al [106] have recently postulated that the 
variety of observed radiation effects at low doses may reflect different 
functional consequences that are specific for both cell type and cellular 
environment. What triggers the response is a matter of speculation: it may 
be an unspecific stress response, possibly with the induction of heat shock 
proteins or it may even relate to the effects of LDHRS on specific non- 
malignant cell populations, i.e. the involvement of differential induction of 
cellular repair mechanisms.
It is also postulated that LD-RT induced apoptosis in peripheral blood 
mononuclear cells (PBMC) [107,108], causes an increase in the secretion of 
anti-inflammatory cytokines such as IL-10 and a decrease in the secretion of 
pro-inflammatory cytokines, TNF-alpha, IL-1 and IL-12, from activated 
monocytes. Interleukin 10 (IL-10), in addition to having potent anti­
inflammatory and immunosuppressive activity, has demonstrated significant 
inhibitory effects on tumour growth, development of metastases and 
angiogenesis in a number of tumour types, including melanoma, in-vitro 
[109,110]. If the radioresistant tumours that we have treated were sensitive to 
such changes, this could explain the outcomes we observed in the low dose 
treatment regime.
Another possible explanation for these results that warrants exploration is 
the oxygenation status of the tumour nodules. Tumour oxygenation is 
recognised as an important determinant of the outcome of radiotherapy, it 
being generally accepted that hypoxia has a radio-protective effect, anoxia 
increases radioresistance by a factor of 2.5-3. Large numbers of clinical and 
experimental studies have demonstrated that tumour hypoxia has a direct 
effect on clinical outcome in many tumour types including sarcoma and 
melanoma [111-118].
There are a limited amount of data regarding the effects of oxygen status on 
the low dose response of cells, but assessment of the effects of hypoxia on 
LDHRS in vitro suggest that not only does it persist in hypoxic conditions, 
but that hypoxic tumours may actually be relatively more sensitive at very 
low doses than oxic tumours. In the only cell line where this has been 
studied in detail, Chinese hamster V 79 cells, the data indicate that hypoxic 
cells are also hypersensitive to low doses of radiation and exhibit an 
increased radioresistance response, albeit triggered at the slightly higher 
dose of ~0.7Gy (c.f. 0.5Gy) compared to oxic cells [40]. Mathematical 
modelling studies have taken these observations one step further. Dasu and 
Denekamp modelled four hypothetical cell lines using LQ/IR model and
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demonstrated that at very low doses per fraction in a fractionated regime, 
hypoxic protection could be reduced, abolished or even reversed [119]. 
Further studies by the same group, using more cell lines, have gone so far 
as to suggest that 0.5Gy fractions may be more effective than oxygen 
mimetic chemical sensitisers [120]. They suggest that there is an optimum 
dose around 0.4-0.6Gy where hypoxic protection can be minimised if cells 
show inducible repair [42]. They concluded that the use of a standard low 
dose per fraction (of 0.5Gy) for all the cell lines came very close to 
minimising the hypoxic protection without the need to individualise the 
regime for each cell line, and that the potential benefit of ultrafractionation in 
minimising hypoxic resistance is greatest in those cells showing the highest 
intrinsic radioresistance.
These factors may be relevant to our observations if the melanoma and 
sarcoma nodules were hypoxic during treatment. Although nodules in the 
size range included in this study are unlikely to show a significant level of 
hypoxia, relative hypoxia compared to other tumour types could have 
increased the effect of low dose fractions compared to larger fractions 
specifically in these tumours. We have no histological material with which to 
confirm or refute this. Also, as there was a significant difference in volume 
between the two groups of nodules, those being treated with 
“ultrafractionation” being larger (p=0.002), it might be expected that this 
would effect the outcome, but if anything it would probably be in favour of 
the conventionally treated nodules as those treated with “ultrafractionation” 
are more likely to be hypoxic.
Whatever the mechanism, if the hypersensitive response in these 
radioresistant tumour nodules is real it has far reaching implications as it 
suggests that there may be a therapeutic advantage to using 
"ultrafractionated" radiotherapy regimens in the treatment of radioresistant 
tumour types. Such tumours would include melanoma and sarcoma, which 
were included in this study, but may also include other tumours that exhibit 
both clinical radioresistance and a high SF2 in vitro. One tumour type that 
warrants investigation is glioblastoma multiforme (GBM). It is designated 
"radioresistant" on the basis of in-vitro data (SF2) [121-124] and in-vivo data 
(TCD50) [125] and has an appalling clinical outcome with virtually no long­
term survivors. "Ultrafractionated" radiotherapy may be applicable to these 
tumours, as LDHRS has been demonstrated in both glioma cell lines 
[9,10,11,28,126,127] and xenograft models [10,59].
In summary, in this study "ultrafractionated" radiotherapy appears to confer 
an advantage over conventionally fractionated radiotherapy in terms of 
tumour growth delay in metastases from "radioresistant" tumours. This is in 
accordance with a significant amount of laboratory data that demonstrates 
LDHRS in tumour cell lines and suggests that the same effect occurs in- 
vivo.
There are considerable inconsistencies in the literature between the results 
obtained in-vitro, in-vivo, in animals and clinically. Until now there have 
been no clinical data to support the hypothesis that radioresistant tumour 
types respond favourably to low dose per fraction radiation. This study, 
although small, adds to the body of evidence that point towards the 
existence of LDHRS in "radioresistant" tumours.
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4.2. Normal Skin
4.2.1. Effect on Basal Cell Density
Historically speaking, the first evidence of an enhanced effect of low doses 
per fraction came from Joiner et al's 1986-study [50] looking at mouse skin. 
Using a "top-up" experimental design and assessing functional end-points, 
they demonstrated that at doses of less than 0.6Gy per fraction the LQ 
model under-predicted the effect of the radiation. This experiment suggested 
a maximal enhanced sensitivity factor of 2.88 for mouse skin, with maximum 
enhancement at doses of 0.1-0.2Gy per fraction. This study was the starting 
point for all subsequent investigation into LDHRS.
The evaluation of epidermal basal cell density in the study of the biological 
effects of ionising radiation is well documented [6,7,12,64], Previous studies 
note a wide distribution of normal basal cell density in both human and 
animal skin specimens. The reasons quoted for this distribution include 
inherent biological variation and technical factors such as differences in the 
size of biopsy, the methods of tissue fixation, cell counting and 
measurement of the basement membrane length.
The effects of low dose per fraction radiation on normal skin demonstrated 
in this study need to be seen in the context of skin physiology and the 
normal response of skin to radiation. As stated earlier the epidermis is a 
constantly renewing, hierarchical type of tissue with cellular proliferation
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occurring in the basal and suprabasal layers [78,82] and having a 
generation time of about 2.6 days. The minimum transit time for a labelled 
basal cell to pass from the basal layer, through the other layers and be shed 
from the corneal layer is about 26 days [81]. After exposure to radiation 
there follows a dose dependent reduction in stem cells, resulting in a 
decrease in the influx of cells into the transit cell compartment. Pre-existing 
differentiated cells have an unaltered life span and in the absence of further 
proliferation, this would result in thinning of the epidermis with flattening of 
the papillae. If the entire differentiated population of epidermal cells is lost 
before a new transit cell compartment is re-established from a sufficient 
number of stem cells then loss of the skin surface will occur. After a number 
days, following irradiation, there is a marked fall in the thymidine labelling 
index and the mitotic index of basal cells [82]. The rate of cell loss in pig skin 
has been shown to be 2.6% per day following single and fractionated 
irradiation and is independent of the final radiation dose [65]. The time to the 
appearance of the early skin reaction and its rate of increase are also 
independent of the final dose, because they are related to cell loss and this 
continues at the pre-irradiated rate. In contrast to this the peak reaction and 
the extent of degeneration are related to the total dose: they relate to the 
proportion of surviving stem cells.
These models suggest that the rate of reduction in basal cell density 
following exposure to radiation is independent of dose given, and cell loss 
occurs at a rate equivalent to its natural turnover time i.e. in the absence of 
proliferation, differentiation and cell loss will continue at the same rate.
Two previous studies assessing changes in human epidermal basal cell 
density after different single doses of radiation, suggest a disproportionate 
decrease in basal cell density when doses of ~0.5Gy per fraction are 
compared with doses of ~1Gy per fraction or more [6,63]. The first of these
studies by Turesson et al [6] compared the 
mean BCD response at different total doses given as 0.45 vs 1.1 Gy per 
fraction in 40 patients. The data suggested a significant reverse fractionation 
effect, meaning a greater effectiveness per unit dose of 0.45Gy compared to 
1.1Gy on the cellular density of the basal cell layer. The ratio of the slopes of 
these dose relationships was termed the "Dose Modifying Factor" (DMF) and 
a value of 1.8 was quoted. The second of these studies used a very similar 
technique and compared doses of ~0.5 and >1Gy per fraction [63]. The ratio 
of the slopes of these dose relationships was termed the "Enhancement 
Ratio" (ER) and here a value of 2.03 was quoted, equivalent to Turesson's 
1.8 (DMF). These results may reflect the existence of LDHRS in vivo but this 
model has some limitations that are discussed below.
One hypothesis to explain the observed differences in BCD in both these studies 
is that the cells receiving a higher dose per fraction may initially sustain a higher 
cell kill in a shorter period, which stimulates early proliferation restoring the BCD 
to near original levels more rapidly in the higher dose per fraction group. The 
confounding effects of cellular repopulation could therefore mask a true 
biological effect on cell killing. However neither of these studies demonstrate a 
marked relative decrease in BCD for the higher dose fields at earlier time points, 
which would be expected if this hypothesis were correct. In other studies
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[66,128], the onset of cell proliferation in skin has been observed from around 
day 21 regardless of the dose per fraction used. The majority of patients in the 
Shah study [63] completed treatment by 28 days with no suggestion of an 
overshoot in the BCD counts from the high dose side after day 21 i.e. no 
enhanced proliferation. Immunohistochemistry of proliferative markers, for 
example Ki-67, quantifying the proportions of cells in cycle would have been 
useful in corroborating the above data. In the Turesson study [6], the Ki-67 
index was assessed - it was observed to be depressed below the value in 
unirradiated skin during the first 3 weeks of radiotherapy, followed by a 
significant increase during the next 4 weeks -equivalent in both treatment 
groups. For both high and low dose fields one conclusion could be that cellular 
repopulation may actually obscure the effect of the LDHRS phenomenon by 
rapidly replacing lost cells.
In addition to this, it could be argued that the accumulation of dose in unit time at 
the basal cell layer is less on the low dose side than on the high dose side. As 
each fraction was delivered with a 24-hour interfraction interval the resulting 
cumulative skin dose on the low dose side is always approximately 50% that of 
the high dose side. A standard plot of BCD versus skin dose for both of these 
studies demonstrates a reduction in BCD for the low dose side that is about 
twice that for the high dose side. See Figures 1.7 and 1.8 (Chapter 1)
If, however, the Shah data is re-analysed, plotting the BCD against time from the
start of irradiation, this apparent effect is lost, figure 4.1, suggesting no
significant sensitisation with low dose radiation.
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Figure 4.1. Dose response for basal cell density in skin. BCD versus Time. 
Right hip dose >1 Gy/fraction, left hip dose ~0.5Gy/fraction. Error bars 
removed for clarity. “ER” = 0.718 (95%CI 0.659-0.781)
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This BCD vs time result could, however, still be interpreted as being consistent 
with the presence of LDHRS, as reduction in BCD is equivalent at given times on 
both sides despite the fact that the low dose side has only received half the dose 
compared to the high dose side. However, the results could also be interpreted 
as a “non-specific” effect in which the rate of cell loss from the basal layer is 
independent of the dose given. This interpretation would be consistent with the 
model discussed earlier and put forward by Hopewell et al using data from the 
large white pig [129].
The study described in this thesis was initiated primarily to assess the difference 
between "ultrafractionated" and conventionally fractionated regimes on 
metastatic tumour nodules, but it also allowed comparison of the effects of 
regimes of equal dose intensity on normal skin. It was hoped that the information 
yielded by this study would help to distinguish between the two possible 
hypothetical models mentioned above, by eliminating time as a confounding 
factor and by simultaneously assessing proliferation in the basal cell 
compartment. The results lend support to the second interpretation, i.e. that a 
sequence of events is triggered following exposure to ionising radiation and that 
this sequence is independent of the dose given. The fact that the “ER” in this 
study (0.75) is very similar to that found when the data from the Shah study is 
re-analysed (0.718) would support this, as would the similar proliferative 
responses seen in both treatment groups in this study. In summary, therefore, 
the findings of Turesson [6] and Shah [63] suggest that LDHRS might exist in 
human skin, but each study was bound by the same limitations i.e. not taking 
into account the difference in dose intensity. It is interesting to note that in both
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these studies, the enhancement ratio (“ER”), as quoted by Shah, or dose- 
modifying factor (“DMF”), as quoted by Turesson [6], approximate to 2 which is 
essentially the factor by which the time is different at any particular dose point. 
When the Shah data is re-analysed, taking the time factor into account, the 
apparent “reverse fractionation effect” is lost.
In our study we have taken this one step further, by ensuring equal dose 
intensity and demonstrating similar proliferative responses between the 2 arms, 
our data would appear to point to some sparing for the “ultrafractionated” arm. 
This would be in keeping with a normal fractionation effect, due to some repair 
occurring between fractions.
There are, however, a number of issues that need to be raised in regard to the 
interpretation of this study, firstly a direct comparison cannot be made with either 
of the previous studies [6,63] as the doses per fraction in the high dose arms are 
different (>1Gy & 1.1 Gy vs 1.5Gy). This difference is important as 1.5Gy /fraction 
would be expected to produce a larger effect per unit dose than ~1Gy /fraction 
which could partially explain the "loss" of the LDHRS effect. Secondly, it may be 
that the 4-hour interfraction interval used in our study is too short to allow 
enough time for full restitution of the LDHRS effect between successive fractions 
or, thirdly, that the 0.5Gy per fraction dose was too great to cause a 
hypersensitive response, although the same remarks could be made about the 
other studies [6,63]. In the original work by Joiner et al [50] the effect was most 
marked at lower doses than those used in this study (0.1-0.2Gy per fraction) and 
larger gaps were left between treatments (8-hr inter-fraction intervals). More
143
recently and also using changes in BCD as the endpoint, Dorner et al [55] failed 
to demonstrate LDHRS in the skin of nude mice using 0.4Gy TDS (inter-fraction 
interval -  4 hours) x 6 weeks. However, in a follow-up study using 0.2Gy x 6 
times per day (inter-fraction interval -  4 hours) to a total dose of 7.2Gy the 
phenomenon was evident.
Another, although less likely, explanation for this result is that the tumour 
nodules exert some sort of humoral effect on the surrounding skin causing it to 
become "stressed" and in doing so "lose" it's LDHRS.
It should be stressed at this stage that basal cell density is not a direct measure 
of epidermal cell clonogenic survival and therefore may not be the optimal 
endpoint with which to assess the radiation response of skin. A more appropriate 
method to determine whether or not LDHRS exists in normal human skin may be 
that described by Van der Aardweg et al which assesses clonogenic survival 
following radiation exposure directly [130,131]. They have demonstrated that the 
use of full thickness epidermal sheets, cultured in vitro, are suitable for the 
assessment of colony formation following exposure to ionising radiation and that 
epidermal radiosensitivity can be estimated from quantification of colony 
numbers.
In summary, data from previous studies supported the existence of LDHRS in 
normal skin using BCD measurement as the endpoint [6,63]. Our study, which 
excludes time as a confounding factor, contradicts this evidence, albeit in a 
limited number of patients Our data also suggest that even if LDHRS does occur
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in skin it is unlikely to be biologically relevant as proliferation is dose independent 
and easily overcomes any cell loss.
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4.2.2 Effect on Proliferation
Human epidermis is a renewing cell population in which the rate of cell 
production equals the rate of physiological loss. Following an insult, i.e. 
radiation, the production rate tends to increase and remain high until the 
damage is repaired. How this process is controlled is not fully understood. To 
study the mechanism of this response, experimental work has been carried 
using the so-called "stripping" technique, whereby the stratum corneum layer is 
repeatedly removed by application of adhesive tape [83]. The period of post­
injury recovery has been studied using a variety of techniques, including 
observation of mitotic figures [83,132,133], autoradiography [134] and flow 
cytometry [135]. Two possibilities have been proposed.
The first possibility is that, in human epidermis there is a resting GO population 
of cells that has the potential to divide and that these resting cells are recruited 
into cycle from GO following a certain stimulus [136,137]. Boezeman et al [139], 
using a mathematical analysis of DNA distribution at different times following 
injury, have suggested that a GO population does indeed exist in resting 
epidermis in vivo and that following "stripping" with adhesive tape these cells are 
recruited into cycle.
Another possible explanation for the proliferative response is that there is a 
decrease in cell cycle time, which is brought about by a more rapid transition of 
cells from S into G2. In other words cells in cycle “speed up" in an effort to 
compensate for cell loss [139,140].
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Ki67 antigen is expressed in late G1, S, G2 and M phase (but not GO) of the cell 
cycle and can be used as a marker for the growth fraction i.e. the actively 
proliferating cell pool [85,96]. Although some authors have stated that the 
fraction of cells showing Ki67 immunoreactivity may overestimate the growth 
fraction in tumours [97] it is accepted to be representative in normal tissues [96]. 
Cyclin A is responsible for the progression of cells through S-phase and the 
transition between G2 and M phases [98,99] and is expressed after the 
restriction point in G1, i.e. in S, G2/M and the early part of M [99]. Therefore, 
although also a marker of proliferation, it's expression is short-lived in 
comparison to Ki-67; the results here reflect this, as the proliferative index 
assessed by Cyclin A was lower than that assessed by Ki-67.
We assessed the Cyclin A: Ki-67 ratio at each time point as a surrogate for 
accelerated repopulation as it was taken as being representative of the 
number of cells occupying S and G2 phase in the growth fraction. In the 
untreated (pre-radiation) cells the Cyclin A positive fraction is expected to be 
30 to 50% of the Ki-67 positive fraction. This value in our study was 45.3 ±
3.01 (SE).
This pre-irradiation value of -  45 appears quite high when compared with 
results quoted from other studies, but it is important to note that the cell 
cycle kinetics of skin are by no means consistent in the literature. Castelijns 
et al [96] have calculated the S: GF ratio as being -15%, but they only 
assessed S-phase cells, counted the cells in all layers of the epidermis and
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counted per mm of the epidermis. Another study by the same group using 
flow cytometric methods calculated the percentage of basal cells occupying 
S and G2M as 5.5 [141]. A number of other flow cytometric studies quote 
values of 2.7 - 7.0 for cells in S and G2M [138,142,143,144]. These data are 
much more in keeping with our value of 4.81.
It is known that the percentage of cells occupying each phase of the cell 
cycle is effected by a number of external factors, namely age, time of year 
and part of the body [142]. On top of this, the proliferative response is a very 
complex issue; it is probably a mixture of perturbation due to cell cycle 
delays, alterations in cell cycle kinetics and recruitment of cells into cycle: 
neither Ki67 nor cyclin A may be the ideal markers with which to assess 
which of these is the main factor.
There is evidence in haematopoetic cells that Ki67 may not be expressed 
(or at least detectable) during the first transit of recruited cells through the 
GO to G1 transition [145], therefore it may not be a sensitive marker of 
recruitment. It is not known if this is the case in epidermal cells. Also, as 
cyclin A is expressed in both S and G2 it will be effected by any radiation 
induced G2 delays and thus its level might not drop. However as Ki67 is not 
metabolised until mitosis, its expression would also be effected by a G2 
delay. The fact that we are not seeing a significant fall in cyclin A relative to 
Ki67 suggests that higher levels of expression are due to more rapid cell 
cycling.
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Although it is difficult to extrapolate information from static parameters into 
kinetic explanations, the changes in Cyclin A: Ki-67 ratio following radiation 
in this study are interesting. They would suggest that although the labelling 
indices (LI) are falling during the first 5-10 days in both treatment groups, the 
skin is already compensating, as the fall in Cyclin A LI is not as great as the 
fall in Ki-67 LI. This would be consistent with either speeding up of the cell 
cycle of the surviving cells or with cells being recruited into cycle to replace 
the damaged cells. The expression levels observed are more consistent with 
an increase in the rate of cell cycling during the initial period where both the 
Ki67 and the cyclin A fall as if the effect were purely due to cells being 
recruited into cycle the growth fraction would be increasing. The fact that the 
ratio is still higher than the untreated skin at day 26 would suggest that the 
epidermis has still not fully recovered i.e. there is still cell death triggering 
the process or the "healing" process is not complete.
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4.3. Conclusion
In this study "ultrafractionated" radiotherapy appears to confer an advantage 
over conventionally fractionated radiotherapy in terms of tumour growth 
delay in radioresistant tumours. This is in accordance with a significant 
amount of laboratory data that demonstrates LDHRS in tumour cell lines and 
suggests that the same effect occurs in-vivo.
Until now there have been no clinical data to support the hypothesis that 
radioresistant tumour types respond favourably to low dose per fraction 
radiation. This study, while adding to the body of evidence that point towards 
the existence of LDHRS in "radioresistant" tumours, is small and does not 
answer the question definitively.
With regard to the effect of multiple low dose radiation exposures on normal 
skin, our study contradicts the previously available data, and suggests that 
LDHRS does not occur in skin. Also, given the almost identical proliferative 
responses seen following "ultrafractionated" radiation and the more 
conventionally fractionated radiation, even if it does occur it is unlikely to be 
biologically relevant as proliferation easily overcomes any cell loss.
The combination of these data (tumour nodules and normal skin) suggests a 
potential therapeutic window that could be exploited, by the use of 
"ultrafractionated" radiation as a treatment option for tumours traditionally 
described as radioresistant. Obviously further studies need to be performed
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to resolve whether "ultrafractionation" consistently results in greater 
response in "radioresistant" tumours and to confirm the mechanisms 
underlying the phenomenon, which may provide a biological marker for 
tumours that show LDHRS and enable this effect to be fully exploited 
clinically.
It is also important to bear in mind, that the data presented here only reflect 
what happens when small volumes of normal skin are exposed to doses of 
0.5Gy. Until we have a clearer understanding of the mechanisms that 
govern the response in this low dose region, these data cannot be used to 
predict the possible outcome if larger volumes of normal tissue were to be 
exposed to low doses of radiation (as in IMRT treatments), nor can they be 
used to predict risk of cancer induction following low dose radiation 
exposure.
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CHAPTER 5: INVESTIGATION OF LDHRS IN Hs633T SARCOMA CELL 
LINE IN-VITRO
5.1. Introduction
The aim of this thesis is to ascertain whether LDHRS can be demonstrated 
in-vivo in normal tissues and in metastatic tumour nodules. One of the 
specific tumour types of interest is soft tissue sarcoma because it is 
radioresistant both in-vitro and clinically and a number of patients with 
metastatic sarcoma were included in the study (see Chapter 2). In vitro data 
using sarcoma cell lines is limited; we therefore carried out a series of 
parallel laboratory experiments to assess whether these tumours exhibit 
LDHRS in vitro following multiple low dose radiation exposures. We used a 
cell line that had previously been shown to exhibit LDHRS to single low 
doses. The aim was to compare survival after fractionated low dose 
exposures to equivalent single conventional doses. A similar dose schedule 
to that in the clinical study was used: 0.5Gy TDS X4 days vs 1.5Gy OD X4 
days.
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5.2. Materials and Methods
5.2.1 Cell line
The cell line used for the in-vitro experiment was Hs633T, a human 
fibrosarcoma cell line. It is a cell line that has previously been shown to 
exhibit LDHRS to single doses [pers. comm. S. Short]. See Figure 5.1. The 
cell line was supplied by The European Collection of Animal Cell Cultures 
(ECACC), ref. 89050201. It was originally established at The American Type 
Culture Collection (ATCC). This cell line is tumorigenic in nude mice.
5.2.2 Cell maintenance and sub-culture in vitro
Human tumour cell lines were grown as attached monolayers in Corning
plastic tissue culture flasks (25, 75 or 150cm2) with canted necks and plug 
seal caps. Monolayers were grown in Eagle's minimum essential medium 
(EMEM) supplemented with 10% fetal calf serum (FCS). The culture flasks 
were maintained at 37°C in a CC>2-enriched atmosphere (nitrogen with 5% 
CO2 and 5% O2 ) in Queue cell culture incubators with their caps loose. For 
all cell manipulations the flasks were transferred to a class II safety cabinet. 
Cells were routinely sub-cultured when they reached 50-70% confluence.
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For sub-culture flasks were transferred from the incubator to a safety cabinet 
and the medium was poured the off the cell monolayer into 2.5% 
hypochlorite solution. The monolayer was washed by adding 5-10 ml 
phosphate buffered saline (PBS) to the flask, re-capping it and gently 
rotating the fluid over the growth surface. The PBS was then poured off and 
5-10 ml of pre-warmed calcium-free salt solution containing 0.1% trypsin 
and 0.04% EDTA was added. The flask was then re-capped and shaken 
gently, then the growth surface was inspected using a Nikon Diaphot 
inverted microscope under 40pmagnification. When the cells could be seen 
floating in the trypsin solution an equivalent volume (5-10 ml) of pre-warmed 
EMEM was added to the flask to neutralise the trypsin. The time taken to 
remove cells from the growth surface varied between cell lines from 
approximately 0.5-5 minutes. The resulting cell suspension was then 
decanted into a labelled 20 ml plastic universal, which was then centrifuged 
at 1000 rpm for 5 minutes. The supernatant was then poured off leaving a 
cell plug, which was then whirl-mixed momentarily. The resulting cell 
suspension was then diluted, usually at 1:3 or 1:5, and aliquots were re­
plated to plastic culture flasks. The re-plated flasks were then labelled and 
returned to the incubator.
5.2.3 Mycoplasma testing
All cell lines were tested for mycoplasma contamination before use and at 
six-month intervals thereafter. To test for mycoplasma cells were sub­
154
cultured into flasks containing antibiotic-free EMEM in which they were 
maintained for 3 days prior to testing. They were then removed from the
growth surface using EDTA/trypsin and approximately 2 x 10^ cells were 
inoculated to a covered slide (‘Flaskette’ chamber slide 177453 Nunc) with 
5 ml of EMEM and placed in an incubator for 72 hours. The medium was 
then poured off and the cell layer was washed with fixative (3 washes with 
3:1 methanol: acetic acid at 5 minute intervals) and left to air dry. The cells 
were then stained with a 0.05 pmmM solution of Hoechst stain
(Benzimidazole 33258 at 0.05 pgmM), which was left in contact for 10 
minutes. The stain was washed off with double distilled water and the 
preparation was then inspected using a Nikon UFX-II microscope under UV 
illumination. The preparation was carefully inspected for bright cytoplasmic 
staining in discrete dots, which represents Mycoplasma contamination. An 
infection rate of 0.4% can be detected using this method. Lower rates can 
be detected if a larger number of cells are plated and stained [146].
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5.2.4 Flow cytometry and Cell Sorting
(A) The Fluorescence Activated Cell Sorter (FACScan) is an automated 
cell analyser attached to a computer. Cell analysis is based on the principles 
of flow cytometry in which cells and cell sub populations are recognised 
based on their light scattering and reflecting properties when they are 
illuminated by laser light. Unstained cell populations can be recognised 
based on cell size (forward scatter of laser light) and granularity (side 
scatter). Cellular stains, which produce characteristic fluorescence, can also 
be used to differentiate sub-populations. The cells to be analysed are 
enclosed in a pressurised saline solution and passed through a flowcell 
where they are illuminated and generate up to 5 signal pulses 
simultaneously. These pulses are processed by an analogue-digital 
converter and stored and then further processed by the computer system for 
analysis.
In this experiment we used a Becton-Dickinson FACScan for the flow 
cytometry studies. See Figure 5.2. This FACScan is capable of measuring 5 
optical parameters simultaneously; forward and side scatter and 3 different 
spectral regions of fluorescence. It has an air-cooled 15-milliwatt Argon-ion 
laser with an excitation wavelength of 488 nm. The sensors consist of 3 high 
performance photo multipliers with band pass filters of 530, 585 and >650 
nm. The computer system displays the optical information as either a 
frequency histogram which shows the fluorescence intensity plotted against 
the number of events, or as a dual parameter correlated plot (dot plot) which
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displays one parameter plotted against another. These computer-generated 
cytograms can be further analysed by setting polygons around the 
populations of interest for which the computer will generate statistical 
information.
(B) The Cell Sorter (CS) is a flow cytometer with an additional sort facility. 
In addition to the recognition of cell populations based on optical 
parameters, the cell sorter enables sub-populations of cells to be selected 
and individual cells from the selected population to be sorted and collected. 
It utilises a droplet sorting method in which the cells exit the flow chamber in 
a jet, which breaks up into regular droplets. The droplets contain the cells of 
choice, which have been selected using the computer system described 
above by gating a subset of cells on a cytogram. The cells of choice are 
charged and passed through a high voltage electrostatic field when they are 
deflected and so can be sorted as they emerge into a petri dish or flask. The 
cells are sorted individually and the exact number sorted can be displayed 
during the sorting process. A droplet sorting method is illustrated 
diagrammatically in Figure 5.3
In this experiment a Becton-Dickinson FACS Vantage cell sorter was used 
to sort and count unstained live cells. See Figure 5.4. A sterile cell 
suspension was introduced into the flow cell and single live cells were 
selected from the cell population by analysing the cytogram dot-plot of 
forward against side scatter. This displays cell doublets, debris and single 
cells as separate regions and the single live cells were selected for sorting
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using the computer system to generate a polygonal area around this 
population only. As these cells were sorted they were simultaneously 
counted and the count was displayed on the Vantage console. An exact pre­
determined number of live cells could therefore be sorted into a dish or flask 
and used for cell survival experiments. The method is a modification of that 
described by Durand [5] and used by Wouters and Skarsgard [24,147].
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Figure 5.1. Survival of asynchronous Hs633T human sarcoma cells 
irradiated with 240kVp X-rays measured using the cell-sort protocol. Each 
data point represents 10-12 measurements. [S. Short, unpublished].
159
Figure 5.2. Becton-Dickinson FACScan
160
A ir  pressure
▼ I  Sheath Pressure
.Regulator
Sheath Fluid 
Reserviour
Transducer
Charging Pulse f
Sorting
Logic Control
Sheath Line
Pinch Valve
Negative High 
Voltage Plate
Left Sort
o 
o 
o
o °  
o o
z O \  Sample Pressure 
W  Regulator
Positive High 
Voltage Plate
Transducer
Frequency
Generator
0
Right Sort
>  To Waste
Figure 5.3. Diagrammatic representation of sorting method. The droplets 
containing selected cells are electrically charged as they pass through a 
high voltage electrostatic field and are deflected into a dish or flask.
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Figure 5.4 Becton-Dickinson FACSVantage cell sorter.
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5.2.5 Measurement of cell survival after low-dose irradiation using the 
Cell Sorter
On the day before Cell Sort experiments twenty-four 25-cm2 flasks were 
prepared. 5 ml fresh EMEM was added to each dish or flask and they were 
placed in an incubator at 37°C in a C02-enriched atmosphere (nitrogen with 
5% CO2 and 5% O2) for 8-12 hours. Human tumour cells were harvested 
from monolayer growth in culture flasks using trypsin/EDTA, decanted into a 
plastic universal and centrifuged at lOOOrpm for 5 minutes to produce a cell 
pellet. The cell pellet was whirl mixed momentarily then 5 ml of fresh EMEM 
was added to the universal. The resulting cell suspension was passed 
through a 21-gauge needle attached to a 5 ml syringe 10-20 times to reduce 
cell clumps and whirl mixed again immediately before sorting. Aliquots of 
this cell suspension were decanted into 5 ml, round-bottomed polystyrene 
sample tubes (Becton Dickinson Labware 'Falcon 205L' tubes) which were 
positioned below the Vantage sampling port. 500-1500 cells were sorted 
directly into 25-cm2 flasks. The number sorted depended on the radiation 
dose each one would receive. The exact number sorted in each flask was 
recorded on a standard result sheet and on each flask. Flasks were then 
placed in a cell culture incubator in a CC>2-enriched atmosphere (nitrogen 
with 5% CO2 and 5% O2) to allow the cells to attach. When all the flasks 
had been sorted and left for 30-60 minutes to allow cell attachment the 
flasks were irradiated (see next section for radiation protocol). Following 
irradiation on each day (days 1-4) triplicates were trypsinised and re-sorted 
from 2 flasks from each dose group. These flasks or dishes were returned to
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the incubator and left for 10-14 days to allow for colony formation. They 
were then removed from the incubator and the medium was poured off. 
Approximately 2-ml crystal violet was then added to each flask or dish and 
left in contact for 20 minutes. This was then poured off and the flasks or 
dishes were rinsed twice in tap water. They were left to drain and dry at 
room temperature for 48 hours then the stained colonies could be counted 
manually using a colony counter. This is summarised in figure 5.5.
5.2.6 Irradiations
In the in vitro experiments irradiations were carried out using a Pantak X-ray 
unit at 240 kVp with 0.25 mm Cu and 1.2 mm Al filters and HVL 1.3 mm Cu to
give a dose rate of 0.2 Gy min-1 for doses less than 1 Gy and 0.44 Gymin-1 
for doses greater than 1 Gy. This change in dose rate at low doses was 
necessary because at doses below 1 Gy the time taken to give each dose at 
the higher dose rate is very short (less than 7 seconds for 0.05 Gy) and the 
time taken for the Pantak shutter to open is a significant proportion of this 
time. Reducing the dose rate reduced this 'shutter error'. In addition the 
flask(s) were arranged parallel to the shutter to reduce the effective opening 
time across the field defined by the flasks. No difference in cell survival has 
been found at these doses for changes in dose rate at low doses [13]. 
Flasks were irradiated in a Stuart perspex incubator heated to 37°C. This 
thermostatically controlled plastic housing can be kept at constant 
temperature whilst in position below the Pantak head. A plastic tray with cut­
outs for 6 petri dishes or 6 X 25 cm^ culture flasks was placed inside the
164
incubator and dishes or flasks were positioned on this tray in the pre­
determined positions. If less than 6 flasks or dishes were used the remaining 
positions were filled with dummy flasks, containing 5 ml of medium. The 
temperature and atmospheric pressure were recorded at the start of the 
irradiations and regularly during irradiation and used to calculate the 
dosimeter divisions per gray for each dose separately. 0 Gy control flasks 
were positioned inside the incubator for 3 minutes without activating the 
Pantak unit. The time of starting and finishing each dose was recorded with 
the flask number(s), dose received and dosimeter divisions. A Pantak X-ray 
unit is shown in Figure 5.6.
In this experiment the effect of 2 radiation regimes on Hs633T cell line were 
compared. 0.5Gy TDS (4hr interfraction gap) X 4 days was compared with 
1.5Gy OD X 4 days as follows. On day 1, 8 flasks were irradiated with OGy, 
8 flasks were irradiated with 1.5Gy and 8 flasks were irradiated with 0.5Gy 
TDS. Four hours after the last irradiation, triplicates were sorted from 2 
flasks from each dose group. On day 2, 6 flasks were irradiated with OGy, 6 
flasks were irradiated with 1.5Gy and 6 flasks were irradiated with 0.5Gy 
TDS. Four hours after the last irradiation, triplicates were sorted from 2 
flasks from each dose group. This protocol was repeated on day 3 with 4 
flasks in each dose group and on day 4 with 2 flasks in each dose group. 
See figure 5.5.
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Surviving fractions were calculated for each dose group on each day as 
follows:
P.E of treated observations 
P.E of untreated observations
No. Cells observed 
No. Cells plated
Where S.F is surviving fraction and P.E is plating efficiency.
Surviving fraction was then plotted against time for each dose group.
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Figure 5.5. Hs633T Split Dose Experiment
Day 1
Irradiate 8 flasks @ OGy 
Irradiate 8 flasks @ 1.5Gy
Irradiate 8 flasks @ 0.5Gy X 3 @ 6.00am, 10.00 am & 2.00 pm 
4 hr after last treatment (6.00 pm) sort triplicates from 2 flasks from each 
dose aroup and return to incubator X 10-14 davs
Day 0
Hs633T cells grown to 60-70% confluency and plated to T25 flasks as follows 
5E5 cells for day 2 
2E5 cells for day 3 
1E5 cells for day 4
5E4 cells for day 5 at 6 flasks per day 
Warm up Pantak
^ Remaining flasks 
Day 2
Irradiate remaining 6 flasks @ OGy 
Irradiate remaining 6 flasks @ 1.5Gy
Irradiate remaining 6 flasks @ 0.5Gy X 3 @ 6.00am, 10.00 am & 2.00 pm
4 hr after last treatment (6.00 pm) sort triplicates from 2 flasks from each
dose group and return to incubator X 10-14 days
^ Remaining flasks 
Day 3
Irradiate remaining 4 flasks @ OGy
Irradiate remaining 4 flasks @ 1.5Gy
Irradiate remaining 4 flasks @ 0.5Gy X 3 @ 6.00am, 10.00 am & 2.00 pm
4 hr after last treatment (6.00 pm) sort triplicates from 2 flasks from each
dose group and return to incubator X 10-14 days
^ Remaining fiasks 
Day 4
Irradiate remaining 2 flasks @ OGy
Irradiate remaining 2 flasks @ 1.5Gy
Irradiate remaining 2 flasks @ 0.5Gy X 3 @ 6.00am, 10.00 am & 2.00 pm
4 hr after last treatment (6.00 pm) sort triplicates from 2 flasks from each
dose arouo and return to incubator X 10-14 davs
Figure 5.6. Pantak X-ray machine with a Stewart incubator used to keep 
the cells at 37°C during the irradiations.
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5.3 Results
The results of the experiment comparing the effects of the two radiation 
regimens on asynchronously growing Hs633T human sarcoma cell line are 
shown in Table 5.1. The cell line received either 1.5Gy once daily for four 
days or 0.5Gy TDS (interfraction gap of 4 hours). These data demonstrate 
no enhanced killing from multiple small doses per day compared with the 
same nominal dose given as once daily fractions. These data are 
demonstrated in Figure 5.7. This result is in contrast to that obtained when 
the same cell line is exposed to single low dose exposures. See figure 5.1.
Of note, however, is that the surviving fractions on day 2 are significantly 
different, with greater cell kill in favour of the "ultrafractionated" treatment. 
By applying the single fraction data for Hs633T, we can calculate the 
predicted surviving fraction assuming LDHRS occurs following each 
successive fraction in this experiment. These data are plotted in Figure 5.9.
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SPECIAL NOTICE
DAMAGED TEXT - INCOMPLETE IMAGE
Day OGy
plated
OGy
counts
OGy
pe
OGy
sf
0.5Gy
plated
0.5Gy
counts
0.5Gy
pe
0.5Gy
sf
1.5Gy
plated
1.5Gy
counts
1.5Gy
pe
1.5Gy
sf
I 605 183 0.302 1.000 619 85 0.1373 0.4541 812 119 0.1465 0.4846
I 609 204 0.334 1.107 651 88 0.1351 0.4470 817 96 0.1175 0.3886
i 619 204 0.329 1.089 643 112 0.1741 0.5760 815 159 0.1950 0.6452
I 619 175 0.282 0.935 816 105 0.1286 0.4255 824 102 0.1237 0.4093
l 613 184 0.300 0.992 614 100 0.1628 0.5386 820 111 0.1353 0.4476
I 613 162 0.264 0.874 615 114 0.1853 0.6130 827 132 0.1596 0.5278
614 177 0.288 0.953 860 57 0.0662 0.2192 1015 122 0.1201 0.3975
D 571 193 0.338 1.117 884 93 0.1052 0.3479 1001 121 0.1208 0.3997
D 615 216 0.351 1.161 825 73 0.0884 0.2926 1005 114 0.1134 0.3751
•) 624 176 0.282 0.932 814 72 0.0884 0.2925 1009 105 0.1040 0.3441
■> 614 179 0.291 0.964 812 81 0.0997 0.3299 1017 119 0.1170 0.3869
D 621 167 0.268 0.889 838 102 0.1217 0.4025 1034 126 0.1218 0.4030
3 609 196 0.321 1.064 824 55 0.0667 0.2207 1033 67 0.0648 0.2145
3 605 229 0.378 1.251 812 64 0.0788 0.2606 1012 86 0.0849 0.2810
3 605 226 0.373 1.235 817 72 0.0881 0.2914 1016 66 0.0649 0.2148
j 613 223 0.363 1.203 818 66 0.08060. 0.2668 1078 72 0.0667 0.2208
3 607 197 0.324 1.073 813 52 0639 0.2115 1009 89 0.0882 0.2917
,i 609 248 0.407 1.346 813 62 0.0762 0.2522 1041 77 0.0739 0.2446
4 619 202 0.326 1.079 814 34 0.0417 0.1381 1705 59 0.0346 0.1144
4 624 197 0.315 1.044 818 32 0.0391 0.1293 1195 36 0.0301 0.0996
4 626 186 0.297 0.982 813 44 0.0541 0.1789 1506 50 0.0332 0.1098
4 662 212 0.320 1.059 806 31 0.0384 0.1272 1516 62 0.0408 0.1352
4 614 201 0.327 1.082 817 35 0.0428 0.1416 1504 67 0.0445 0.1473
4 625 210 0.336 1.111 839 39 0.0464 0.1537 1524 45 0.0295 0.0976
Table 5.1. Asynchronous Hs633T human sarcoma cells. A result of 
irradiations over 4 days, given as either 0.5Gy doses at 4-h intervals or 
1.5Gy single doses once daily. Surviving fraction = sf, plating efficiency =  
pe.
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Figure 5.7. Survival of asynchronous Hs633T human sarcoma cells. A 
result of irradiations over 4 days, given as either 0.5Gy doses at 4-h 
intervals or 1.5Gy single doses once daily. Error bars are SEM. Overall 
multiple low doses per day did not demonstrate enhanced cell killing 
when compared with the same dose given as a single fraction. SF =
Surviving Fraction.
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Figure 5.8. Survival of asynchronous Hs633T human sarcoma cells. A result of 
irradiations over 4 days, given as either 0.5Gy doses at 4-h intervals or 1.5Gy 
single doses once daily. SF = Surviving Fraction. The red line demonstrates SF 
of Hs633T cells assuming LDHRS at each fraction and no proliferation between 
fractions.
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5.4. Discussion and Conclusion
Although the phenomenon of LDHRS is well established there are limited 
data available on the effect of multiple consecutive low doses. The results 
obtained in this multifraction experiment are in contrast to predictions from 
the results of single fraction experiments, assuming a hypersensitive 
response to each fraction. See Figure 4.8. Hs633T human sarcoma cell line 
has clearly demonstrated LDHRS to single low dose exposures and the 
reasons that it has not demonstrated the phenomenon to multiple low dose 
fractions need to be explored.
The effect of the "adaptive" response on LDHRS and the relationship 
between it and LDHRS/IRR are uncertain. In classically described "adaptive" 
responses, a small "priming" dose produces enhanced resistance to a 
second "challenge" (usually higher) dose [14-17]. It is a distinct possibility 
that these two mechanisms share the same underlying process and that in 
some cell lines, in some circumstances an initial "priming" dose may initiate 
an "adaptive" response with increased radioresistance that abolishes 
LDHRS to subsequent low doses. In V79 hamster cells, which demonstrate 
LDHRS, small "priming" doses of radiation have been shown to induce 
resistance to "challenge" doses down to 0.05Gy delivered six hours later 
[18]. However this "adaptive" response appeared to be dose dependent, 
with doses in the range ~0.2Gy being more effective at abolishing 
"challenge" dose LDHRS than higher doses. In addition to this, 
cyclohexamide has been shown to inhibit the induction of induced
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radioresistance (IRR) in the same cell line, thus demonstrating that protein 
synthesis is a requirement for the development of IRR. The "adaptive" 
response in this cell line is also inhibited by cyclohexamide [18]. This lends 
some support to the theory that these two phenomena are manifestations of 
the same underlying mechanism. As cyclohexamide inhibits protein 
synthesis, at least it suggests that both phenomena depend on de-novo 
protein synthesis, although not necessarily the same proteins.
However, this study [18] was limited to challenge doses of <1Gy and so an 
evaluation of the response at doses of >1Gy was not possible. Wouters and 
Skarsgard [7] studied the effects of consecutive low doses on HT29 cells, 
again a cell line that exhibits LDHRS to single low doses [9,148], and their 
results, while being consistent with those of Marples et al, offer a different 
explanation. Like the findings in the V79 cells, irradiation of HT29 cells 4hrs 
after a priming dose of 0.3Gy resulted in no LDHRS to the second dose. If, 
however, the response beyond 1Gy was studied it was seen to be, if 
anything, more sensitive than the unprimed population. Therefore there was 
no protection afforded by the 0.3Gy "priming" dose in these cells with 
respect to total doses of >1Gy. At total doses of 0.5-0.8Gy i.e. 0.3Gy 
"priming" dose followed by up to 0.5Gy "challenge" doses, they reported an 
increase in resistance relative to the single dose which may be attributed to 
an "adaptive" response.
Another possible explanation for the contradictory results between single 
and multiple low dose exposures in this cell line can be made on the basis of
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cell-cycle effects. The efficiency and type of DNA repair and hence the 
radiosensitivity of cells is known to vary with position of cells within the cell- 
cycle in the high dose range. Short et al [11] initially suggested that similar 
variations may occur in the low dose range and then went on to study the 
effects of cell-cycle phase on the low dose response in two glioma cell lines 
[25]. This study suggested that the low dose response of both these cell 
lines alters when cells are irradiated during different phases of the cell cycle. 
In T98G, a cell line that demonstrates LDHRS/IRR, although the 
phenomenon was present in all phases, it was most marked in the G2 
population of cells.
In the U373 cells, which had previously not demonstrated LDHRS/IRR in the 
asynchronous population, LDHRS/IRR was clearly demonstrated by those 
cells in G2. They concluded that LDHRS is primarily a response of G2 
phase cells and that this response dominates that seen in asynchronous 
populations. This obviously has implications for fractionated low dose 
exposures, as the movement of cells into more or less sensitive phases of 
the cycle will impact on the magnitude of the hypersensitive response. 
Clearly the movement of cycling cells into more sensitive cell-cycle phases, 
such as G2, between successive low doses has the potential to markedly 
enhance the low dose response.
Another potential confounding factor may be the time interval between 
successive irradiations. In this experiment a 4-hr interval was used, this may 
be too short to allow restitution of the hypersensitive response, or too long
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allowing significant cellular proliferation to occur. It has been known for 
some time that the phenomenon is dependent on the time interval between 
fractions. Short et al [20] studied the effects of multiple fractions of radiation 
on 4 different cell lines (T98G, U87, A7 and U373) and demonstrated that 
when consecutive low doses are delivered LDHRS only occurs, to each 
dose, when the doses are separated by certain intervals. In T98G, which 
demonstrates LDHRS to single irradiations, a second hypersensitive 
response was only seen when intervals of 2-6 hrs had elapsed, the same 
was true for A7 (2-8 hrs) and U87 (1-5 hrs), both of which show LDHRS to 
single low doses. However, in all four cell lines the surviving fraction 
increased with increasing time between fractions, this was felt to be due to 
cellular proliferation. In our experiment there was an overnight gap between 
successive irradiations (16-hrs) and some cell division may have occurred, 
but this should be equivalent between single and multi-fraction doses. 
Therefore it would cause a spurious increase to be observed in the surviving 
fraction, thus obscuring the LDHRS effect. In the same experiments, quoted 
previously, Short et al studied the effects of cellular proliferation between 
successive fractions. They demonstrated that qualitatively similar changes in 
surviving fraction with time between doses occurred in both asynchronous 
and G1 arrested cell populations. They postulated that although the extent 
of the LDHRS effect may be modulated by cell cycle position, cell cycle 
progression is not the underlying cause of the variation in surviving fraction 
seen following doses separated by differing times; it is more likely due to 
changes in underlying repair processes.
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In another multi-fraction experiment Smith et al [43] studied the effects of 
fractionated low dose y-rays on both C3H 10T1/2 mouse embryo cells and V- 
79 Chinese hamster cells. The cells were exposed to 6Gy of y-rays, given in 
fractions of 6Gy, 3Gy, 2Gy, 1Gy or 0.3Gy with time intervals of 3 hrs. They 
concluded that there was no evidence of any increased effect at doses of 
<1Gy inconsistent with those predicted by the LQ formula. These data must 
be interpreted in the light of a number of issues. Firstly, it should be noted 
that a 3-hour interfraction interval was used, which is shorter than that used 
in other experiments and may not be optimal. Secondly, the response of 
C3H10T1/2 to single low dose exposures had not previously been 
investigated- so the lack of HRS following fractionated doses could be 
explained by the fact that HRS does not occur at all in this cell line. As 
regards the V79 cell line, although it is known to exhibit HRS to single low 
doses, the effect is smaller than in other cell lines. Marples and Joiner [13] 
have shown that in the V79 cell line pre-treatment with x-rays can produce a 
priming effect that takes 6-24 hrs to diminish. It is therefore not surprising 
that there is no evidence of LDHRS in this cell line following exposure to 
multiple low dose fractions separated by only 3-hrs.
In many of the single fraction low-dose experiments that demonstrate 
LDHRS, doses of 0.4Gy per fraction were used. It may be that the dose of 
0.5Gy used in this multiple fraction experiment is too high to elicit the 
LDHRS response.
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Another possible explanation for the results of this experiment is that 
LDHRS may only occur over the first few fractions of the treatment regime 
with the effect then wearing off. This would be supported by the fact that at 
day 2 there is a significantly different surviving fraction for the multi-fraction 
regime compared with the single fraction regime, but as more time passes 
this effect disappears.
It is apparent from previous studies that the response to a second dose 
following an initial dose is dependent on a number of factors, namely dose, 
cell-line used and the time interval between successive fractions. This 
experiment merely highlights these issues and does not rule out the 
existence of LDHRS/IRR in this cell line. It does, however, raise similar 
questions as previous studies: if the LDHRS/IRR phenomenon is to 
exploited clinically then the time interval between fractions is as crucial as is 
the dose given.
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CHAPTER 6. THE FEASIBILITY OF AN "ULTRAFRACTIONATED" 
RADIOTHERAPY REGIME IN POOR PROGNOSIS HIGH-GRADE 
GLIOMAS 
6.1 Introduction
6.1.1 High Grade Gliomas (HGG)
Malignant gliomas are the commonest tumours of the CNS accounting for 
>50% of all such tumours in adults. The majority of these tumours are high- 
grade tumours (HGG), such as anaplastic astrocytoma and glioblastoma 
multiforme (GBM) - WHO grade III and IV respectively. These tumours are 
aggressive, highly invasive and neurologically destructive and are 
considered to be among the deadliest of human cancers.
Progress in the treatment of these tumours has been slow, in the most 
aggressive manifestation, glioblastoma multiforme (GBM); the standard of 
care has remained essentially unchanged for the last two decades: maximal 
safe surgical resection followed by postoperative radiation therapy ± 
chemotherapy. The prognosis of patients with GBM remains dismal despite 
improvements in neurosurgical and radiotherapeutic approaches [149], with 
the median survival being in the range of 9-12 months. Clearly there is a 
need for novel therapeutic approaches in order to improve survival rates in 
this patient population.
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In the absence of a universally accepted staging system the prognosis of 
these tumours is based on a variety of clinico-pathological factors such as 
age, performance status and histology. By using these parameters these 
patients can be broadly classified into favourable and poor prognosis 
groups. Patients in the favourable prognosis subgroup are younger, have a 
good performance status and have a median survival of 12-24 months. 
Conversely in the poor prognosis group median survival is much reduced, 
being in the region of 6-9 mths.
6.1.2 Current Management Options
(A) Surgical resection
To date no prospective randomised controlled trials comparing surgical 
resection with no resection have been carried out. A number of investigators 
have retrospectively analysed the relationship between extent of surgical 
resection and outcome [150-152] and the consensus of opinion is in favour 
of more extensive resection where possible. Simpson et al [150] found 
median survival rates of 11.3 mths following complete resection, 10.4 mths 
following partial resection and 6.6 mths following biopsy alone. Other 
investigators [151,152] have reproduced these results. However, these 
studies are retrospective and as such are subject to selection bias in that the 
extent of the resection is influenced by the size of the tumour and the 
patient’s general condition and performance status.
180
(B) Postoperative Radiation Therapy
Conventional Fractionation
Surgery alone achieves median survival rates of only -14 weeks in GBM 
[149]. Two large studies have compared best supportive care with post­
operative radiotherapy [153,154]. The BTSG 69-01 [153] study showed an 
improvement in median survival from 14 weeks to 36 weeks in favour of 
radiotherapy while Kristiansen et al [154] found median survival in the 
patients who received radiotherapy to be 10.8 mths compared with 5.2 mths 
in those patients managed with best supportive care. Post-operative 
radiation treatment therefore remains standard therapy. Because of the fact 
that >90% of these tumours will relapse at or immediately adjacent to the 
primary site, a number of studies have been instituted to assess the need for 
whole brain radiotherapy (WBRT). These studies demonstrated no 
significant difference in survival rates for WBRT compared with local field 
treatment, which is now standard [155,156].
With regard to the issue of radiation dose, the evidence supports total doses 
of 50-60Gy using fractions of 1.8-2Gy. Of a number of studies assessing 
dose only the MRC (UK) study [157], which compared 60Gy in 30 fractions 
with 45Gy in 20 fractions, has shown a statistically significant benefit in 
favour of the higher dose. The joint ECOG/RTOG study [158] comparing 
60Gy with 70Gy found no advantage to the increased dose, nor did the
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addition of a brachytherapy boost to 50Gy in 25 fractions (ensuring a 
peripheral tumour dose of at least 60Gy) confer any advantage [155].
Altered Fractionation
The main aim of hypofractionation is to achieve equivalent tumour control 
with a shortened radiation regimen. The risk with this type of treatment is 
that there may be an increased incidence of late radiation morbidity. In the 
sole randomised study addressing this issue Glinski & colleagues [159] 
compared conventional RT with a hypofractionated regimen (3 courses of 
RT separated by a one-month intervals - the first 2 courses were 20 Gy in 5 
fractions over 5 days to the whole brain, and the third a 10 Gy 'boost' over 5 
days). They found at a preliminary analysis that the 2-year survival for GBM 
was significantly better in the hypofractionated arms (23% vs. 10%, p< 
0.05).
Another option is to hyperfractionate i.e. to reduce the fraction size and/or to 
accelerate the treatment i.e. to give more than 1 treatment per day. A 
number of studies [160-173] have been carried out over the last decade 
comparing hyperfractionated and/or accelerated regimes with conventionally 
fractionated regimes in HGG and, in general the results have been 
disappointing. Only a single randomised trial has shown an improvement in 
median survival time in favour of the accelerated, hyperfractionated arm 
[168] and even then the gain in median survival was less than 3 months.
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(c) Postoperative Radiation and Chemotherapy
Several studies have addressed the role of additional chemotherapy with 
postoperative radiotherapy with conflicting results. A meta-analysis of 16 
randomised trials of radiotherapy +/- chemotherapy [174] suggested an 
improvement in median survival in favour of the radio-chemotherapy 
patients (12 months versus 9.4 months), but the prognostic factors were not 
comparable and there was a greater number of young, well patients in the 
combined treatment group. Brada et al [175] in the largest MRC trial to date 
found no conclusive evidence to support the addition of chemotherapy to 
radiotherapy in the treatment of HGG.
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6.1.3 Poor Prognosis High Grade Gliomas (HGG)
As stated earlier, due to the lack of a universally accepted staging system 
the prognosis of these tumours is based on a variety of clinico-pathological 
factors including age, performance status and histology.
Most of the clinical trials studying high-grade gliomas have been carried out 
in young, good performance status patients, using standard management 
with surgery plus radiotherapy with the poor prognosis patients being 
excluded. However in the poor prognosis group of patients, who comprise 
60% of patients with high-grade gliomas the same management may not be 
appropriate. These patients are usually older or have a poor performance 
status and the median survival is in the region of 6-9 mths -  they correspond 
to the RTOG [176] recursive partitioning analysis group V and VI and have 
MST of 4.8 months.
The optimum treatment for these patients is not well defined -  some 
practitioners treat with shortened courses of radiotherapy and others 
recommend symptom control wit best supportive care only.
No randomised studies have specifically studied the effects of postoperative 
radiotherapy in poor prognosis high-grade glioma patients. In the studies 
quoted earlier [153,154] an accurate assessment of the effects of 
radiotherapy on these patients cannot be made because as the studies were 
not stratified according to prognostic factors.
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A small number of retrospective studies have shown an improvement in 
median survival in patients with poor prognosis HGGs who received 
adjuvant radiotherapy when compared with those who received no 
radiotherapy (23-45 weeks vs. 6-9 weeks, p< 0.05) [177,178].
With regard to altered fractionation regimes, although there are no 
randomised trials comparing conventional radiotherapy with 
hypofractionated radiotherapy in these poor prognosis patients there is a 
significant amount of level III and IV evidence to suggest that 
hypofractionated radiotherapy may be equivalent [179-187]. There are no 
studies assessing the effects of hyperfractionated or accelerated regimens 
in the poor prognosis patient group. It is apparent, therefore, that there is not 
a clearly defined optimum treatment for poor prognosis high-grade glioma 
patients, in whom standard approaches yield generally poor results.
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6.1.4 "Ultrafractionation" as a Feasible Treatment Option in High Grade 
Glioma (HGG)
It is widely accepted that the inherent radioresistance of some tumours is an 
important factor limiting the radiocurability. In vitro and clinical 
radioresistance in gliomas has been well-documented
[123,124,188,190,191] and so any means of rendering gliomas more 
sensitive to radiation would be expected to improve local control. Ideally this 
would use a means that increased the effective dose to the tumour without 
increasing the toxic effects on the surrounding normal tissues.
By using an ultrafractionated radiotherapy regimen this may be possible, if 
LDHRS is a phenomenon specific to radioresistant tumour cells and does 
not occur in normal neural tissue.
(A) LDHRS in Glioma
There is a growing body of evidence to suggest that glioma may be a 
tumour that exhibits LDHRS and therefore may be suitable for treatment 
with an "ultrafractionated" radiation regime.
LDHRS has been demonstrated in significant numbers of glioma cell lines 
following single low dose exposures [6,7,11] and Short et al [20] have 
studied the effects of multiple low dose fractions in a number of radio­
resistant human glioma cell lines in vitro. They found LDHRS to be present 
in 5 of 6 cell lines tested; these 5 cell lines had previously exhibited LDHRS
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to single low dose exposures. They suggested that LDHRS was a common, 
if not universal, finding in radioresistant human glioma cells lines and 
concluded that a fractionated course of very low doses produces increased 
cell kill when applied to radioresistant tumour cells in-vitro given an 
appropriate inter-fraction interval. They suggested that the same 
phenomenon might occur in-vivo leading to increased cell killing per gray in 
radioresistant tumours.
In addition to this, Beauchesne [10] studied the effects of an 
"ultrafractionated" regimen on 3 further glioma cell lines and reported a 
dramatic decrease in cell survival in 2 of these with the “ultrafractionated” 
regime -  both of these cell lines had previously demonstrated a 
hypersensitive response to single low dose fractions.
The data for a hypersensitive response in glioma in vivo following low 
radiation doses are conflicting. Short [59] compared the effects of 0.4Gy 
TDS (interfraction interval of 6hrs) with 1,2Gy OD, each for 30 days, on a 
T98G glioma tumour xenograft in nude mice. T98G is a cell line that has 
demonstrated LDHRS to both single fraction and multiple low dose fractions 
in in-vitro cell survival assays. The results of in-vivo "ultrafractionation" 
demonstrated an increase in mean growth delay in favour of the 
"ultrafractionated" regime (313.68 days vs 138.39 days) but this did not 
reach statistical significance. Similarly, Beauchesne [10] compared the 
effects of 0.8Gy TDS (interfraction gap of 4 hours) with the same biologically 
equivalent dose in 2Gy fractions OD on a G152 glioma xenograft. Tumour
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re-growth rate in the mice treated with the “ultrafractionated” regime was half 
that in the mice treated conventionally (p<0.05).
In contrast to these data, Krause et al [60] compared the effects of an 
“ultrafractionated” regime (0.4Gy TDS X 6 weeks) with a more 
conventionally fractionated one (1.68Gy OD X 30 fractions) using an A7 
glioma xenograft in nude mice. They demonstrated a significant 
improvement in local tumour control in the conventionally treated tumours 
(p<0.05). Of note, although the A7 cell line exhibits LDHRS to single fraction 
low doses, the effect following multiple fractionated low dose exposures was 
much smaller than would be predicted from single dose studies [pers. 
comm. S Short]. This may explain the lack of effect in-vivo.
Therefore, the same group proceeded to repeat the in-vivo experiment using 
a T98G glioma xenograft, and the early data, also, appears not to 
demonstrate an advantage to the "ultrafractionated" regime [personal 
communication - M. Baumann],
(B) LDHRS in Normal Brain Tissue
Although HRS has not been investigated in brain tissue, studies examining 
rat spinal cord have shown no evidence of increased radiosensitivity with 
doses of 0.4Gy per fraction. In fact the reverse may be true, with more 
sparing than would be predicted by the LQ equation with low doses per 
fraction [57], This would suggest that using “ultrafractionated” treatment
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regimens to treat malignant brain tumours would allow large fields to be 
treated without increasing toxicity to normal brain. Using the experimentally 
derived induced repair parameters for cell lines that demonstrate LDHRS in 
vitro, it can be shown that an ultrafractionated regimen could be almost 
twice as effective as if the same total dose were given as 2Gy per fraction. 
For example, if T98G were the target tumour and kidney the critical normal 
tissue, 141 fractions of 0.5Gy giving a total dose of 70.5Gy would be 
equivalent to 117Gy in 2Gy fractions to the tumour and 60Gy to the normal 
tissue [6]. This increased effective tumour dose in the absence of increased 
toxicity to surrounding brain tissue would result in an increased therapeutic 
ratio.
In summary, these data are conflicting, but when added to the results of the 
tumour nodule study (chapter 3, [189]), which showed a statistically 
significant increase in tumour growth delay in "radioresistant" tumours 
following an "ultrafractionated" regime, they suggest that there may be a 
therapeutic advantage to using "ultrafractionation" in the treatment of HGG: 
a tumour that exhibits clinical, in-vitro and in-vivo radioresistance
[123,124,125,190,191].
It was against this background, and given that there is no generally 
acceptable treatment for poor prognosis HGG that a feasibility study was 
initiated investigating the use of an "ultrafractionated" regime in this patient 
population. It was anticipated that this would lead to a larger Phase II study,
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with the aim of ultimately performing a randomised study comparing an 
"ultrafractionated" regime with a standard palliative radiation regime.
6.1.5 Imaging Studies
Imaging studies provide an objective method of quantifying tumour response 
to treatment. As well as measuring tumour shrinkage (volume response to 
treatment), functional (physiological) parameters can also be assessed. 
Objective tumour shrinkage has long been widely adopted as a prospective 
end point for definitive clinical trials used to estimate the benefit of a 
treatment in a specific group of people, but a change in size may be delayed 
chronologically, often not becoming apparent until late in treatment or after 
completion of treatment. Reports from the functional imaging literature 
suggest that metabolic and physiological changes in tumour precede size 
changes. Therefore, functional imaging studies have the potential to provide 
early evidence of treatment effects and these may then be used as 
surrogate end points [192],
Commonly, tumours are characterised by neovascularisation and increased 
angiogenic activity. [193-195] As a consequence, tumours may have a high 
proportion of immature and therefore hyper-permeable blood vessels. It has 
been demonstrated in a number of animal models [196,197] that DCE-MRI 
can be used to quantify microvascular permeability in tumours.
Unlike conventional enhanced MRI, which simply provides a snapshot of 
enhancement at one point in time, DCE-MRI permits a fuller depiction of the
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wash in and wash out contrast kinetics within tumours, and therefore 
provides insights into the nature of the bulk tissue properties and blood flow.
In most tissues except the brain, testes and retina, the contrast agent rapidly 
passes into the extravascular-extracellular space (EES, also called leakage 
space - ve) at a rate determined by the permeability of the microvessels, 
their surface area and by blood flow. In tumours, typically 12-45% of the 
contrast media leaks into the EES during the first pass [198]. The transfer 
constant (Ktrans) describes the transendothelial transport of low molecular 
weight contrast medium. Three factors determine the behaviour of low 
molecular weight contrast media in tissues during the first few minutes after 
injection; blood perfusion, transport of contrast agent across vessel walls 
and diffusion of contrast medium in the interstitial space. If the delivery of 
the contrast medium to a tissue is insufficient then blood perfusion will be 
the dominant factor determining contrast agent kinetics and Ktrans 
approximates to tissue blood flow per unit volume [199]. This condition is 
commonly found in tumours. See Figure 6.1.
As low molecular weight contrast media do not cross cell membranes, the 
volume of distribution is effectively the EES (ve). Contrast medium also 
begins to diffuse into tissue compartments further removed from the 
vasculature. Over a period of several minutes to hours, the contrast agent 
diffuses back into the vasculature from where it is excreted (usually by the 
kidneys). When capillary permeability is very high, the return of contrast
medium is typically rapid resulting in faster washout as plasma contrast 
agent concentrations fall.
MRI sequences can be designed to be sensitive to the vascular phase of 
contrast medium delivery (so-called T2* methods which reflect on tissue 
perfusion and blood volume) [200,201]. T1-weighted sequences are 
sensitive to the presence of contrast medium in the EES and thus reflect 
microvessel perfusion, permeability and extracellular leakage space.
Susceptibility-weighted (T2*-weighted) spin-echo sequences are more 
sensitive to capillary blood flow compared with gradient-echo sequences, 
which incorporate signals from larger vessels [202], The degree of signal 
intensity loss is dependent on the vascular concentration of the contrast 
agent, microvessel size [203] and density.
Tracer kinetic principles can be used to provide estimates of relative blood 
volume (rBV), relative blood flow (rBF) and mean transit time (MTT) derived 
from the first-pass of contrast agent through the microcirculation 
[200,201,204]. See Figure 6.5. MTT is the average time the contrast agent 
takes to pass through the tissue being studied. The most robust parameter 
that can be extracted reliably from first pass techniques is rBV, which is 
obtained from the integral of the data time series during the first pass of the 
contrast agent [205]. Absolute quantification of T2*W DCE parameters can 
be obtained by measuring the changing concentration of contrast agent in 
the feeding vessel, and in this way, quantified perfusion parameters in
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normal brain and of low grade gliomas have been obtained [206,207]. From 
a practical perspective, it is not always necessary to quantify T2*-weighted 
DCE-MRI data to obtain insights of the spatial distribution of tissue 
perfusion. Simple subtraction images can demonstrate the maximal signal 
attenuation, which in turn has been strongly correlated with relative blood 
flow and volume in tumours (208,209). See Figure 6.6.
DCE-MRI was chosen as an appropriate investigative tool in this study as it 
was felt that it measured useful surrogate end-points for the evaluation of 
the efficacy and potential toxicity of "ultrafractionated" radiotherapy, as well 
as producing novel data on the radiation response of neural tissues.
6.2 Methods and Materials
This study was designed to investigate the feasibility of using an 
"ultrafractionated" treatment regime to treat high-grade gliomas (HGG). The 
term “ultrafractionation” has been used to define radiotherapy delivered at 
0.5Gy per fraction in multiple fractions per day. In this study we used an 
"ultrafractionated" regimen with a 4-hour inter-fraction interval. Ethical 
approval was granted from Watford and Mount Vernon Hospital NHS Trust 
Ethical Review Committee. The patients receiving the “ultrafractionated” 
treatment were admitted to the hospital for the duration of their treatment.
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6.2.1 Patient Selection
Patients with a histologically proven GBM, who were deemed poor 
prognosis on the basis of age alone (>60 years), or had KPS of >70 were 
deemed eligible for the study. Other eligibility criteria included
• A supratentorial tumour
• Able and willing to give informed consent.
• No previous brain radiation.
• No previous chemotherapy.
• RTOG Prognostic Class V or VI (Median Survival time-4.8 months). See
Table I [176].
Patient numbers
It was hoped to recruit 3 patients into this feasibility study, before recruiting 
patients into a larger Phase II study. However, over a period of twelve 
months only 2 patients with HGG who fitted the inclusion criteria and in 
whom palliative radiotherapy was deemed the appropriate treatment option 
were enrolled. The Phase II study would be designed in such a manner as 
to detect a significant increase in MST.
6.2.2 Investigations
After bolus IV administration of contrast material, multiple images were 
obtained in rapid succession to evaluate the dynamics of tumour 
enhancement. The results were then analysed in a quantitative method to
quantify contrast uptake and, in turn, change in tumour perfusion as they 
were affected by the radiotherapy. In addition to T1 and T2 weighted 
images, other measures obtained included relative blood flow (rBF), relative 
blood volume (rBV), permeability surface area product (Ktrans), 
extravascular-extracellular leakage space (ve), mean transit time (MTT) and 
proton density (PD). Such measurements can be performed together with 
morphological information within 40 minutes. The scanning protocol is 
described below.
(A) Scanning protocol
• MR examinations were performed prior to and following "ultrafractionated" 
radiation treatment on a 1.5T Siemens Symphony scanner.
• Initial T1 and T2 weighted anatomical scans were performed to select an 
imaging plane through the centre of the tumour.
• Eight spoiled gradient-echo images of the central slice position were 
acquired with a range of different echo times (TE 5-75ms, TR 100ms, flip 
angle 40°, slice thickness 8mm) and the rate of signal decay R2* was 
calculated
• A proton density weighted (PD) image was acquired (TR 350 ms, TE 4.7 
ms, flip angle 40 °, slice thickness 8mm).
• Dynamic T1 -weighted images were acquired at a time resolution of 12 
seconds for 40 measurements (TR 11 ms, TE 4.7 ms flip angle 40°, total 
imaging time 8 minutes 5 seconds). Gadopentetate dimeglumine (Gd-DTPA)
was injected IV using a power injector (dose 0.1 mmol/kg) at 4 ml/s during the 
fifth acquisition.
• Tumour regions of interest (ROIs), defined on the contrast-enhancing 
regions on early T1-weighted subtraction images (100 seconds), were drawn.
• Signal intensity was converted to T1 relaxation rate values using the PD 
image, in conjunction with a calibration experiment involving phantoms with 
known T1 relaxation rate values.
Gd-DTPA concentration was calculated for each pixel during the dynamic 
acquisition from the equation:
Ct(t) = (1 /T1 (t) - l/TUO))/^
where Ct(t) is the tissue Gd-DTPA concentration at time t after injection, T'i(O) 
is the baseline tissue T1s Ti(t) is the Ti at time t and Ri is the longitudinal 
relaxivity of protons in vivo due to Gd-DTPA. The Gd-DTPA concentration­
time curve was fitted to the Tofts and Kermode model of permeability10 and 
values for Ktrans and ve were calculated.
• Dynamic T2* images were acquired at a time resolution of 2 seconds for 60 
measurements from a single slice position through the centre of the tumour 
(TR 30ms, TE 20ms, flip angle 40°, total imaging time 2 minutes). A second 
bolus of Gd-DTPA was injected IV using a power injector (dose 0.2mmol/kg) 
at 4 ml/s during the tenth acquisition. The relative maximum signal drop 
(rMSD), which has been strongly correlated with blood volume within tumours, 
was calculated from the signal intensity-time curve.
• A gamma-variate function can be fitted to the resultant signal intensity-time 
curve and maps of semi-quantitative relative blood volume, flow and mean 
transit time can also be derived.
(B) Scanning schedule
Scan 1+2: Pre-treatment (RT) - 2 scans within 5 days in the week leading 
up to the start of the radiotherapy to assess the reproducibility of kinetic 
parameters.
Scan 3: After completion of treatment (~4-6 weeks) to assess response 
(morphological and kinetic). Kinetic analysis to be done on an individual 
patient and group basis after calculating appropriate repeatability statistics 
from scans 1+2.
Scan 4: 12 week after completing treatment to assess further response 
(morphological study only)
The steroid dose was maintained during the period of the MRI studies 
(Scans 1-3) starting 1 week prior to the 1st DCE-MRI
6.2.3 Radiation Protocol
Dexamethasone 8mg per day was prescribed for all patients at initial 
assessment. This was because dexamethasone can alter the findings of the
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DCE-MRI and this ensured that all patients could be assessed in the same 
fashion.
(A) Radiation Dose
Patients entered into the study received an “ultrafractionated” treatment. The 
standard palliative treatment protocol at this institution is 30Gy in 6 fractions 
given over 2 weeks. The "ultrafractionated" regimen was calculated to be 
biologically equivalent to the above “standard” protocol, from a tumour 
point of view, and is 0.5Gy TDS X 29 days. See Appendix I. If LDHRS 
occurs in glioma cells in vivo to the same extent it does in vitro, then this is 
equivalent to 73.1 Gy
(B) Radiation Treatment Plan
Patients were simulated in an immobilisation mask. The treatment was 
planned using conventional methods using CT and/or MRI scans to define 
planning target volumes. The patients were treated supine, using 2 parallel- 
opposed fields, ensuring appropriate margins around the tumour plus 
surrounding oedema (at least 3cm). The dose was prescribed to the mid­
plane and single slice CT films were taken to ensure that the target volume 
was encompassed by the 95% isodose. The patients were treated using 
6MV photons. See Figures 6.2 & 6.3.
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6.2.5 End Points
Feasibility of the "ultrafractionated" treatment. 
Feasibility of the scanning protocol.
Overall survival (OS)
Toxicity of "ultrafractionated" treatment
Class Age (yrs) Histology KPS
(App V)
Mental
status
Symptom
Duration
Surgery Neuro
Deficit
I <50 AA Normal
II >50 AA 70-100 >3/12
III <50
<50
AA
GBM 90-100
Abnormal
IV <50
>50
>50
GBM
AA
GBM
<90
70-100
70-100
>3/12
PR/CR No
V >50
>50
>50
GBM
GBM
GBM
70-100
70-100
<70 Normal
PR/CR
Biopsy
Yes
VI >50
>50
GBM
GBM
70-100
<70 Abnormal Biopsy
Table 6.1. RTOG Prognostic Class -  based on RPA -RTOG [176]
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Injection of IV  contrast
medium (e.g., Gd- 
DTPA) Whole body 
interstitial space
Red
Cell
Fraction
Blood
Plasma
trans = Transfer constant
Tumor 
interstitial 
space (ve)
keP = Rate 
constant
Renal
excretion
Figure 6.1. Body compartments accessed by low molecular weight, gadolinium 
containing contrast media inject intravenously
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Figure 6.2. Plain X-ray (lateral) simulation film of patient 1.Parallel 
opposed lateral fields. The field margins are defined by most inferior light 
field and most anterior and posterior vertical light fields. Iso-centre is 
arrowed.
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Figure 6.3. Patient 1 being placed into immobilisation device and ready 
for treatment
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6.3. Results
Ultrafractionated radiotherapy was administered to 2 patients (1M: 1F) over a 
period of 12 months. Both of the patients had histologically proven grade IV 
glioma (GBM). The patient demographics are presented in table 6.2. Treatment 
was commenced at a mean time of 6.5 weeks from histological diagnosis (range 
3-10 weeks) and 13.5 weeks from onset of first symptom (range 13-14 weeks). 
Both patients completed "ultrafractionated" radiation treatment within the 
specified treatment period, with no interruptions. Table 6.3
"Ultrafractionated" radiation therapy was generally well tolerated with no 
evidence of worsening cerebral oedema, as measured by steroid requirement. 
The only toxicity observed was alopecia: Patient I and Patient 2 developed grade 
II and III alopecia respectively during the course of their treatment. In addition 
Patient 2 developed steroid induced deterioration of his co-existent non-insulin 
dependent diabetes mellitus (NIDDM). This had previously been controlled with 
Metformin 500mg BD, but following initiation of Dexamethasone treatment 
necessitated the addition of Gliclazide 80mg mane and 120mg nocte in addition 
to Insulin given on a PRN basis.
Mean overall survival (OS), as measured from date of diagnosis, was 16.5 
weeks (range 13-20 weeks).
Both patients tolerated the two pre-treatment MRI scans with no problems. 
Patient 1 was too unwell for the first post-treatment scan (at 4-weeks) and
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died shortly after, patient 2 tolerated the first post-treatment scan but also 
died shortly afterwards. The post treatment scan performed on patient 2 
demonstrated significant disease progression with associated cerebral 
oedema. In all the scans performed it was possible to obtain all of the 
desired images. See figures 6.4 - 6.8.
With respect to the feasibility of using an “ultrafractionated" treatment 
regimen in this patient population, all that we can state is that it is feasible in 
our institution. It does however require the provision of 2-3 radiographers 
three times/day including over the weekends, which obviously has cost 
implications for the radiotherapy department.
The scanning protocol lasted 50-60 minutes in each case and, despite this 
long duration, appears also to be feasible, although it is not possible to 
extrapolate from these earlier scans just how well this patient population 
would tolerate later scans of this duration.
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Patient 1 Patient 2
Age 67 years 74 years
Sex Female Male
Presenting symptom Left hemiparesis Left hemiparesis
Date of presenting 
symptom
04/02/03 20/08/03
Date of diagnosis 04/03/03 22/10/03
Means of diagnosis Stereotactic biopsy Stereotactic biopsy
Extent of surgery Biopsy only Biopsy only
Tumour site Right parietal lobe Multifocal disease
KPS 80 80-90
RTOG prognostic 
class
V V
Co-morbid illness N/A NIDDM
Table 6.2. Patient demographics
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Patient 1 Patient 2
Date MRI (1) 06/05/03 12/11/03
Date MRI (2) 08/05/03 13/11/03
Date simulation 02/05/03 07/11/03
Date RT start 12/05/03 19/11/03
Date RT end 09/06/03 17/12/03
Date MRI (3) N/A 13/01/04
Date MRI (4) N/A N/A
Date of death 21/07/03 21/01/04
Overall survival (OS) 20 weeks 13 weeks
Table 6.3. Scanning, planning and treatment dates.
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V (leakage space) Tiw subtraction PD weighted
T2 weighted T 1 weighted
Figure 6.4. Patient 1 pre-treatment scans. MRI (1),
T2*w subtraction
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Rocirculationc 100
Injection of 
Gd-OTPA T u m o r  p e r i p h e r y  
B a c k g r o u n d  
W h r t e  m a t t e r  
G r e y  m a t t e r
50 First pass
0
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Time (minutes)
Mbit*
Pre contrast Nadir 100 seconds
Figure 6.5. Patient 1.T2*-weighted DCE-MRI study.
30 ml of IV contrast Gd-DTPA was given after the 10th data point First 
pass T2* susceptibility effects cause marked darkening of the tumour 
periphery. Darkening of the grey matter of the brain is greater than the 
less vascular white matter. The first pass and recirculation phases are 
indicated. Signal intensity changes for 4 regions of interest are shown in 
the insert (subtraction T2* image of the nadir point for the tumour ROI). 
An anatomic T2-weighted image at the same slice position is also shown 
for reference.
This is a typical T2*-weighted DCE-MRI image of a patient with a 
malignant glioma.
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T im e  (s)
MTT
Figure 6.6. Patient 1. Model fitting of T2*-weighted data and parametric 
map formation.
T2* signal intensity data from figure 2 (tumour periphery) is converted into 
R2* (1/T2*) and then fitted with a gamma variate function. Parametric 
maps representing blood flow kinetics (relative blood flow (BF), relative 
blood volume (BV) and mean transit time (MTT)) are derived on a pixel-by- 
pixel basis. The computed values of rBVy rBF and MTT for this region of 
interest are 509,21.3 arbitrary units and 24 seconds.
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Figure 6.7. Patient 2 pre-treatment scans (MR11).
T i*w  subtraction
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Figure 6.8. Patient 2, Treatment + 1 month scans (MRI 3).
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6.4. Discussion and Conclusions
This study was initiated primarily to assess the feasibility of an 
"ultrafractionated" radiation regimen for the treatment of poor prognosis 
patients with high-grade glioma (HGG). It was planned to recruit patients 
who were designated poor prognosis purely on the basis of age, i.e. patients 
with biopsy proven glioblastoma multiforme (GBM) with excellent to good 
performance status (KPS > 70). It was planned to test feasibility in a small 
group of patients (i.e. 3) before designing a larger Phase II study. It was also 
hoped that valuable information on the effects of low dose per fraction 
radiation on HGG and on normal brain tissue could be evaluated using 
functional imaging.
Mount Vernon Hospital is a cancer centre with a strong tradition in research 
into altered fractionation radiation regimens. The CHART (Continuous 
Hyperfractionated Accelerated Radiation Treatment) and CHARTWEL 
(CHART Weekend Less) radiation regimes for head & neck cancer and non­
small cell lung cancer (NSCLC) were developed and initiated at Mount 
Vernon. These regimes are used on a day to day basis at the centre and 
therefore it is acceptable and indeed standard practice for therapy 
radiographers to treat patients three times daily Mon-Fri and over weekends.
So, although we have demonstrated that "ultrafractionated" radiation 
treatment for HGG is feasible at Mount Vernon, a centre where thrice daily
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and weekend treatment are common place, it is not possible to comment on 
the feasibility of this treatment at other centres where this is not the case.
It is not possible to make any comment of the efficacy of the treatment in 
this patient population based on the small number of patients treated. The 
overall survival values of 13 and 20 weeks are in keeping with what would 
be expected in this patient population following "conventional" palliative 
radiation treatment. The lack of significant toxicity would suggest that the 
treatment is safe, but again it is impossible to comment on any potential late 
effects following this treatment.
With regard to the scanning protocol, it has been demonstrated that it is 
feasible in these 2 patients, but unfortunately no information on treatment 
effect could be ascertained. Patient 2, who had a post-treatment scan, had 
unfortunately progressed following treatment so it was not possible to make 
any comment on alterations in any of the measured parameters following 
"ultrafractionated" radiotherapy
In conclusion, this study set out purely to assess whether or not it was 
feasible to treat patients with HGG using an "ultrafractionated" radiation 
protocol. This study demonstrates that this treatment is feasible, albeit with 
some limitations. There are significant implications as regards staffing, 
hospital admission and cost, which it may not be possible to overcome in 
centres other than this one.
In addition to this, to date only 2 patients have been assessed; it is 
impossible to extrapolate from these to other patients with HGG as these 2 
patients may not be representative of the study population as a whole.
This study would suggest, given the bank of in-vitro and in-vivo data for 
LDHRS in glioma combined with the tumour nodule data and the successful 
application of "ultrafractionation" to these 2 patients, that one additional 
patient is assessed from a feasibility point of view. If the treatment proves 
feasible in this third patient we suggest that the initiation of a Phase II study 
is justified. Obviously, given the significant cost and resource implications of 
this treatment, any benefit from "ultrafractionated" radiotherapy would have 
to be significant to justify general use. This would need to be taken into 
account when designing the Phase II study, i.e. to set the power to be able 
to discern a significant increase in median survival in a small group of 
patients.
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Appendix 1 
Dose Calculations
• The standard protocol for poor prognosis HGG is
30Gy in 6 fractions over 2 weeks
• BED was calculated for both tumour cells and normal brain tissue.
a/p Ratio of 10 was assumed for tumour and an a/p ratio of 3 was assumed for 
normal brain tissue.
• The equation BED = D (1+d/a/p) was used, where
D = total dose received and d = dose per fraction
• BED (tumour) = 30[1+5/10]
= 45Gy
Equivalent to 37.5Gy in 2Gy fractions
• BED (normal tissue) = 30[1+5/3]
= 80Gy
Equivalent to 48Gy in 2Gy fractions
To give equivalent BED to tumour using 0.5Gy fractions
Then 45 = N.0.5 [1+0.5/10] where N is the number fractions needed 
N = 86 [29 treatment days]
ULTRAFRACTIONATED REGIMEN = 0.5Gy TDS X 29 Days
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Assuming HRS exists in Gliomas
Using the IR model D = — p------------- — ---------------------- eq.1
a r \ \  + [^ /a -\}e ' dcj + p d
Where E is effect, D is total dose and d is dose per fraction.
With d = 2Gy
D1° y =  — v n —
a \ \  + {“/ ar^ ) e ^ ) + 2 p
Eq.2
From eq.1 and eq.2
D2Gy a r { \  + [a/a r - ' ) e + pd
D  a r { }  + {a/ a r - ' ) e  2//jc)  +2/3
• ar=a extrapolated from the high (conventional) dose-response, and as is 
the actual aderived from the response at very low doses.
• At very low doses, the IR equation therefore becomes a LQ equation with 
a = as, while at high doses the IR equation becomes a LQ equation with a = a r. 
dc is a parameter describing the range of doses over which the transition from 
LDHRS to IR occurs.
• Using the IR parameters from T98G glioblastoma cells [42] and substituting 
in the above equation with d=0.5Gy.
D2 Gy  1?
D
Therefore, if we assume those high-grade gliomas have exactly the same 
hypersensitivity as glioma cell line then.
D2Gy = 1.7x 43 = 73.1Gv
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CHAPTER 7: SUMMARY OF THE CONCLUSIONS OF THIS THESIS
The objectives of this thesis were threefold. Firstly to assess whether or not 
LDHRS could be demonstrated in normal tissues and malignant tumours 
and secondly to assess if there was a difference between normal tissues 
and tumours that could potentially be exploitable for the treatment of 
tumours classically described as being "radioresistant". If this was the case 
the third objective was to investigate the feasibility of an "ultrafractionated" 
radiotherapy regime in the treatment of a primary "radioresistant" tumour.
With regard to the first objective: does LDHRS exist in normal and malignant 
tissue? The answer appears to be that LDHRS is not exhibited by normal 
skin, but is exhibited by tumours classically described as being 
"radioresistant" such as melanoma and sarcoma, using the 
"ultrafractionated" schedule 0.5Gy TDS (4-hr inter-fraction interval). There 
are a number of possible explanations for this that have been discussed 
previously (see chapter 4). However, if this effect is real and consistent it 
suggests a potential therapeutic window that may be exploitable for the 
treatment of tumours such as melanoma and sarcoma and others such as 
glioma.
It was felt that these data coupled with the considerable bank of in-vitro and 
in-vivo data regarding LDHRS in glioma warranted the initiation of a 
feasibility study assessing "ultrafractionation" in patients with high-grade 
glioma. This feasibility study has demonstrated, albeit in a limited number of
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patients, that the regime of 0.5Gy TDS x 29 days is feasible in this patient 
population. However, it must be said that there are significant manpower 
and cost implications associated with the delivery of this regime, even in a 
department with a long history of delivering multiple fractions per day 
radiotherapy. Any subsequent phase II study would need to demonstrate a 
significant benefit to patients to justify implementation of this regime in to 
standard practice.
With regard to the parallel in-vitro study assessing LDHRS in Hs633T 
sarcoma cell line: the results are slightly disappointing given the fact that this 
cell line exhibits LDHRS to single low dose exposures and the clinical study 
suggests that there is a hypersensitive response to low doses of radiation in 
metastatic sarcoma nodules. Once again, there are a number of possible 
explanations for this that need to be considered namely cell cycle effects 
and interval between fractions. These have been discussed in detail in 
chapter 5.
This thesis demonstrates that the response of "radioresistant" tumours and 
normal tissues to fractionated low doses of radiation differs to an extent that 
may be exploitable clinically for the treatment of these tumours. It also 
demonstrates that an "ultrafractionated" radiotherapy regime for patients 
with high-grade glioma is feasible, albeit with certain limitations. In 
conclusion, therefore, the data generated by this thesis warrant continued 
investigation into the use of "ultrafractionation" for the treatment of high-
219
grade glioma through the continuation of the glioma feasibility and phase II 
studies.
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